MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Cancer Immunity' source. Wed, 21 Sep 2011 14:03:03 +0100 http://www.medworm.com/index.php?rid=5062806&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21714479%26dopt%3DAbstract This study tracks the evolution of one such cancer that developed in a mouse following exposure to ultraviolet light. The primary autochthonous tumor was not highly malignant and was rejected when transplanted into naïve immunocompetent mice. Neoplastic cells isolated from the primary tumor were susceptible to the growth-inhibitory effects of IFNγ in vitro, but expressed very low levels of MHC I antigen and were resistant to tumor-specific T cells unless they were first exposed to IFNγ. Serial passage of the primary tumor cells in vivo led to a highly aggressive variant that caused fast-growing tumors in normal mice. In vitro, the variant tumor cells showed increased resistance to the growth-inhibitory effects of IFNγ but expressed high levels of immunoproteasomes and MHC I molecules a... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=5062806 Tue, 26 Jul 2011 08:30:02 +0100 5062806 http://www.medworm.com/index.php?rid=4821330&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21554088%26dopt%3DAbstract Authors: Brown MP Evaluation of: Wolchok JD, Weber JS, Hamid O et al.: Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 10, 9-14 (2010). For the first time, a pivotal Phase III clinical trial has demonstrated an overall survival benefit for an antimelanoma drug, ipilimumab, in previously treated advanced melanoma patients. Ipilimumab is a T-cell-potentiating monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4. All patients in this study were HLA-A2*0201 positive because the active control arm contained a HLA-A2*0201-restricted peptide derived from the melanocyte differentiation antigen, gp100. Hence, the following question arises: does the survival benefit conferred by ipilimumab... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=4821330 Sat, 30 Apr 2011 23:00:00 +0100 4821330 http://www.medworm.com/index.php?rid=4414912&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21247062%26dopt%3DAbstract In conclusion, LAGE-1a and NY-ESO-1 homology cannot be easily exploited in an anti-NY-ESO-1 vaccine given the low frequency of protein expression detected by IHC or serum analysis. PMID: 21247062 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=4414912 Mon, 31 Jan 2011 04:15:02 +0100 4414912 http://www.medworm.com/index.php?rid=4204443&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21090563%26dopt%3DAbstract Authors: Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4) by ipilimumab leads to immune-mediated tumor regression and immune-related adverse events (irAEs), including diarrhea and colitis. The current analyses were undertaken to promote an understanding of the underlying mechanism of action and to identify potential biomarkers that could help in the prediction and management of ipilimumab-induced gastrointestinal irAEs. Treatment-naïve or previously treated patients with unresectable stage III/IV melanoma (n = 115) received open-label ipilimumab (10 mg/kg every 3 weeks for four doses) and were randomized to receive concomitant blinded prophylactic oral budesonide (9 mg/d with gradual taper th... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=4204443 Sat, 27 Nov 2010 06:30:03 +0100 4204443 http://www.medworm.com/index.php?rid=4171852&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21069948%26dopt%3DAbstract Authors: Dhar S, Chiplunkar SV Aminobisphosphonates are drugs administered for the treatment of bone resorption. They can indirectly activate peripheral γδ T cells and render tumor cells susceptible to lysis by Vγ9Vδ2 T cells. We have investigated the molecules involved in conjugate formation and killing of aminobisphosphonate-treated MCF-7 breast tumor cells by Vγ9Vδ2 T cells. Lysis of aminobisphosphonate (Pamidronate and Zoledronate)-treated MCF-7 tumor cells by Vγ9Vδ2 T cells was assessed by chromium release assays and time-lapse video microscopy. MCF-7 breast cancer cells were chosen as aminobisphosphonates are employed to alleviate bone resorption in this malignancy. Cell cycle profile and expression of MICA, ICAM-I and FasL on aminobisphosphonate-sensitized MCF-7 breast t... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=4171852 Tue, 16 Nov 2010 22:35:03 +0100 4171852 http://www.medworm.com/index.php?rid=4097122&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20957980%26dopt%3DAbstract Authors: Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ Ipilimumab is a fully human, monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor T-cell response. This agent improved overall survival in a phase III trial in previously treated patients with advanced melanoma. Because the mechanism of action for ipilimumab is thought to be HLA independent, most trials enrolled patients without regard to HLA subtype. However, enrollment in the phase III trial was restricted to class-I HLA-A*0201-positive patients because two of the three arms contained an HLA-A*0201-restricted gp100 vaccine. HLA typing was also performed prospectively in several phase II trials and was available for 9... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=4097122 Sun, 24 Oct 2010 13:05:07 +0100 4097122 http://www.medworm.com/index.php?rid=3903469&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20726502%26dopt%3DAbstract Authors: Liggins AP, Lim SH, Soilleux EJ, Pulford K, Banham AH Cancer-testis (CT) antigens/genes show restricted expression in normal tissues but widespread expression in many tumour types. This, coupled with their ability to induce cytotoxic T-lymphocyte responses, makes them attractive vaccine candidates. Following our identification of PASD1, we have used RT-PCR to analyse the mRNA expression profile of a large panel of CT genes in cell lines derived from haematological malignancies, and have studied Sp17 protein expression in the same cell lines and diffuse large B-cell lymphoma (DLBCL) biopsies. Our extensive analysis revealed multiple CT transcripts exhibiting widespread expression across cell lines derived from 21 B- and 4 T-cell malignancies. The broadest mRNA expression profil... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=3903469 Thu, 26 Aug 2010 15:06:03 +0100 3903469 http://www.medworm.com/index.php?rid=3813682&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20672796%26dopt%3DAbstract Authors: Matsutake T, Sawamura T, Srivastava PK Exogenous antigens enter antigen-presenting cells through non-specific mechanisms and are presented by the MHC II molecules. We show here that antigens chaperoned by the heat shock protein gp96 enter dendritic cells and B cells through a specific, CD91- and LOX-1-mediated mechanism, and are presented by MHC II molecules, in addition to MHC I molecules as previously demonstrated. Receptor utilization results in high efficiency uptake such that antigen concentrations as low as 10(-9) M, if chaperoned by gp96, lead to productive antigen presentation. Chaperoning by gp96 increases the efficiency of uptake over un-chaperoned peptides by up to two orders of magnitude. Consistent with these studies in vitro, immunization of mice with gp96-peptid... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=3813682 Tue, 03 Aug 2010 19:03:03 +0100 3813682 http://www.medworm.com/index.php?rid=3787104&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20649179%26dopt%3DAbstract Authors: Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR Expression of the cancer-germline (CG) (or cancer-testis) antigen gene BORIS/CTCFL has been proposed to mediate activation of CG antigen genes in cancer. Consistent with this idea, we have observed that BORIS is frequently expressed in ovarian cancer, often in conjunction with other CG genes. Here we assessed the role of BORIS in CG antigen gene regulation and DNA methylation using normal and cancerous ovarian cell lines, and the CG genes MAGE-A1, NY-ESO-1, and XAGE-1 as models. Adenoviral vectored BORIS was expressed at robust levels and exhibited predominant nuclear localization in ovarian cells. However, BORIS expression in immortalized ovarian surface epithelial cells or ovarian cancer cell lines did not induc... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=3787104 Mon, 26 Jul 2010 08:27:02 +0100 3787104 http://www.medworm.com/index.php?rid=3225190&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20108890%26dopt%3DAbstract Authors: Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ The type I melanoma antigen gene (MAGE) proteins CT7 (MAGE-C1) and MAGE-A3 are commonly expressed in multiple myeloma (MM), and their expression correlates with increased plasma cell proliferation and poor clinical outcome. They belong to the cancer-testis antigen (CTAg) group of tumor-associated proteins, some of which elicit spontaneous immune responses in cancer patients. CT7 and MAGE-A3 are promising antigenic targets for therapeutic tumor vaccines in myeloma; therefore, it is critical to determine if they are immunogenic in MM patients. We analyzed cellular and humoral immune responses against CTAgs in patients with plasma cell dys... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=3225190 Mon, 01 Feb 2010 05:56:13 +0100 3225190 http://www.medworm.com/index.php?rid=3201945&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20092246%26dopt%3DAbstract Authors: Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R Medullary carcinoma (MC) of the breast is a high grade carcinoma that has a relatively favourable prognosis compared to atypical medullary carcinoma (AMC) and other more common breast carcinomas. In a retrospective study in Brunei Darussalam of all available biopsy samples, we compared the nature of the tumour-infiltrating lymphocytes (TILs) in MC and AMC in relation to recorded tumour characteristics. CD4, CD8, CD20, CD25, CD45RO, and CD56 and common tumour biomarkers were detected immunohistochemically. The 11 cases of MC had no nodal metastases and survived without relapse, suggesting good tumour control. In contrast, 7 cases of nodal metastases and 1 relapse were observed in 12 AMCs. Although not statistically significant, the... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=3201945 Sun, 24 Jan 2010 18:02:02 +0100 3201945 http://www.medworm.com/index.php?rid=3165131&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20058853%26dopt%3DAbstract Authors: Mathieu MG, Linley AJ, Reeder SP, Badoual C, Tartour E, Rees RC, McArdle SE The search for novel tumour antigens that are either uniquely expressed or over-expressed in a wide variety of tumours is still ongoing. Because of their expression in a broad spectrum of cancers and limited expression in normal tissues, cancer/testis antigens are considered to be potentially reliable targets for immunotherapy of cancer in general. The helicase antigen HAGE has been identified as a cancer/testis antigen. However, little is known about its expression in normal and cancer tissues. Using a newly developed antibody against HAGE, specific staining of its expression by immunohistochemistry was validated and optimised on murine tumours transfected to express the HAGE protein. The antibody was... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=3165131 Wed, 13 Jan 2010 14:04:03 +0100 3165131 http://www.medworm.com/index.php?rid=3156776&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20052966%26dopt%3DAbstract In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters. PMID: 20052966 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=3156776 Sat, 09 Jan 2010 20:56:02 +0100 3156776 http://www.medworm.com/index.php?rid=2963660&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19877577%26dopt%3DAbstract Authors: Riond J, Rodriguez S, Nicolau ML, al Saati T, Gairin JE Cell surface expression of MHC class I molecules by tumor cells is determinant in the interplay between tumor cells and the immune system. Nevertheless, the mechanisms which regulate MHCI expression on tumor cells are not clear. We previously showed that immune innate cells from the spleen can regulate MHCI expression on MHCI(low) tumor cells. Here, using the murine model of B16 melanoma, we demonstrate that the MHCI status of tumor cells in vivo is regulated by the microenvironment. In subcutaneous grafts, induction of MHCI molecules on tumor cells is concomitant to the recruitment of lymphocytes and relies on an IFNgamma-mediated mechanism. gammadelta T and NK cells are essential to this regulation. A small proportion o... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2963660 Fri, 06 Nov 2009 00:04:02 +0100 2963660 http://www.medworm.com/index.php?rid=2955424&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19877577%26dopt%3DAbstract Authors: Riond J, Rodriguez S, Nicolau ML, Al Saati T, Gairin JE Cell surface expression of MHC class I molecules by tumor cells is determinant in the interplay between tumor cells and the immune system. Nevertheless, the mechanisms which regulate MHCI expression on tumor cells are not clear. We previously showed that immune innate cells from the spleen can regulate MHCI expression on MHCI(low) tumor cells. Here, using the murine model of B16 melanoma, we demonstrate that the MHCI status of tumor cells in vivo is regulated by the microenvironment. In subcutaneous grafts, induction of MHCI molecules on tumor cells is concomitant to the recruitment of lymphocytes and relies on an IFNgamma-mediated mechanism. gammadelta T and NK cells are essential to this regulation. A small proportion o... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2955424 Wed, 04 Nov 2009 03:50:03 +0100 2955424 http://www.medworm.com/index.php?rid=2880035&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19813699%26dopt%3DAbstract Authors: Weinert BT, Krishnadath KK, Milano F, Pedersen AW, Claesson MH, Zocca MB Tumor antigens are the primary target of therapeutic cancer vaccines. We set out to define and compare the expression pattern of tumor antigen genes in esophagus carcinoma biopsies and in an allogeneic tumor lysate-based cancer vaccine, MelCancerVac. Cells used for vaccine production were treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) to determine whether this treatment could improve the profile of tumor antigen genes expressed in these cells. In addition, the presence of MAGE-A tumor antigen protein was evaluated in the purified tumor cell lysate used in the production of the vaccine. Quantitative PCR was used to assay 74 tumor antigen genes in patients with squamous ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2880035 Sun, 11 Oct 2009 03:20:02 +0100 2880035 http://www.medworm.com/index.php?rid=2856400&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19791734%26dopt%3DAbstract Authors: Isobe M, Eikawa S, Uenaka A, Nakamura Y, Kanda T, Kohno S, Kuzushima K, Nakayama E We show correlation between strong and decreased NY-ESO-1-specific immunity with spontaneous regression and subsequent recurrence, respectively, in a long-surviving patient with an NY-ESO-1-expressing lung adenocarcinoma. An integrated immune response consisting of IgG antibody, as well as CD4 and CD8 T cells, against NY-ESO-1 was observed at the time of spontaneous regression of multiple pleural metastases. After tumor dormancy for 3 years, the tumor started to progress. IgG antibody levels and the number of CD4 and CD8 T cells against NY-ESO-1 decreased, but were still detectable. On the other hand, the number of Foxp3+ CD25 high T regulatory cells gradually increased. The findings suggest the... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2856400 Sat, 03 Oct 2009 13:52:02 +0100 2856400 http://www.medworm.com/index.php?rid=2836451&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19777993%26dopt%3DAbstract Authors: Guillaume P, Dojcinovic D, Luescher IF Soluble MHC-peptide complexes, commonly known as tetramers, allow the detection and isolation of antigen-specific T cells. Although other types of soluble MHC-peptide complexes have been introduced, the most commonly used MHC class I staining reagents are those originally described by Altman and Davis. As these reagents have become an essential tool for T cell analysis, it is important to have a large repertoire of such reagents to cover a broad range of applications in cancer research and clinical trials. Our tetramer collection currently comprises 228 human and 60 mouse tetramers and new reagents are continuously being added. For the MHC II tetramers, the list currently contains 21 human (HLA-DR, DQ and DP) and 5 mouse (I-A(b)) tetramer... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2836451 Mon, 28 Sep 2009 01:22:02 +0100 2836451 http://www.medworm.com/index.php?rid=2738289&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19705800%26dopt%3DAbstract Authors: Tchabo NE, Mhawech-Fauceglia P, Caballero OL, Villella J, Beck AF, Miliotto AJ, Liao J, Andrews C, Lele S, Old LJ, Odunsi K Cancer-embryo antigens or developmentally restricted differentiation antigens (DRDAGs), such as PLAC1 (CT92) and developmental pluripotency associated-2 (DPPA2/CT100), are expressed in pluripotent embryonic cells. They are also recognized as cancer-testis antigens (CT) which are proteins normally expressed only in the human germ line but that are also present in a significant subset of malignant tumors. These antigens may prove to be markers of 'repopulating' cells with stem cell-like characteristics and could be critical targets for immunotherapy in epithelial ovarian cancer (EOC). Our objective was to define the frequency of expression and immunogenicit... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2738289 Thu, 27 Aug 2009 19:46:02 +0100 2738289 http://www.medworm.com/index.php?rid=2530565&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19385591%26dopt%3DAbstract Authors: Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M Breast tumours consist of phenotypically diverse populations of breast cancer cells of which only a minority has the ability to form new tumours. The capacity for breast tumour development has been shown to be restricted to breast cancer stem cells with the CD44+/CD24(-/low) phenotype. These cells can resist apoptosis through mechanisms such as the regulation of Bcl-2. Identification of this population of cells is important because of its implication in the development of new therapeutic strategies. One hundred and forty-six primary operable breast cancer patients were investigated in order to identify the population of CD44+ and Bcl-2+ cells in paraffin-embedded tissues by immunohistochemistry. The preva... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2530565 Sat, 27 Jun 2009 14:40:03 +0100 2530565 http://www.medworm.com/index.php?rid=2530564&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19496531%26dopt%3DAbstract Authors: Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD A differentiation antigen commonly expressed on melanoma cells, gp100 is the target of infiltrating T cells. We conducted a phase I randomized cross-over trial of melanoma patients with either xenogeneic (mouse) or human gp100 plasmid DNA injected intramuscularly at three dosages (100, 500 or 1,500 microg) every three weeks for three doses. After the first three injections, patients were then immunized three times with gp100 from the other species. Peripheral blood samples were analyzed at various time points following 10-day culture with gp100 peptides using multi-parametric flow cytometry. A total of 19 patien... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2530564 Sat, 27 Jun 2009 14:40:03 +0100 2530564 http://www.medworm.com/index.php?rid=2305529&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19338264%26dopt%3DAbstract Authors: Oble DA, Loewe R, Yu P, Mihm MC Tumors contain variable numbers of lymphocytes, referred to as tumor infiltrating lymphocytes (TILs). In melanoma, the intensity of this lymphocytic infiltrate is believed to correlate with outcome, though there is some debate about the applicability of this finding for all melanomas. Much research has gone into classifying TILs with respect to antigen receptor structure and the antigen to which melanoma-specific T cells react. However, these studies for the most part did not immunophenotype TILs, and recent data has revealed that the composition of tumoral lymphocytes is not homogenous, but rather represents varying contributions from many lymphocytic subsets. Furthermore, the function of TILs is often compromised as a result of the accumulatio... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2305529 Tue, 07 Apr 2009 07:55:03 +0100 2305529 http://www.medworm.com/index.php?rid=2251181&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19267427%26dopt%3DAbstract Authors: Bauer S, Adrian N, Siebenborn U, Fadle N, Plesko M, Fischer E, Wüest T, Stenner F, Mertens JC, Knuth A, Ritter G, Old LJ, Renner C Polymorphonuclear neutrophils (PMNs) are potent effectors of inflammation and their attempts to respond to cancer are suggested by their systemic, regional and intratumoral activation. We previously reported on the recruitment of CD11b+ leukocytes due to tumor site-specific enrichment of TNF activity after intravenous administration of a dimeric TNF immunokine with specificity for fibroblast activation protein (FAP). However, TNF-induced chemo-attraction and extravasation of PMNs from blood into the tumor is a multistep process essentially mediated by interleukin 8. With the aim to amplify the TNF-induced and IL-8-mediated chemotactic response... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2251181 Wed, 11 Mar 2009 10:46:08 +0100 2251181 http://www.medworm.com/index.php?rid=2198659&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19226101%26dopt%3DAbstract Authors: Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, von Knebel Doeberitz M, Schirmacher P, Weitz J, Grabe N, Jäger D In situ immunohistochemical staining of tumor-infiltrating immune cells in large cohorts of human colorectal cancers has recently supported the hypothesis that the adaptive immune response influences the behavior of human tumors. Tumor-infiltrating immune cells therefore represent a valuable prognostic marker for patients with colorectal cancer, with a high density of immune cells being associated with a good outcome independently of other established prognostic markers. The aim of the present study was to investigate the correlation between infiltrates of immune cells, in either the primary tumor or (where available) the corresponding liver metastases, ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2198659 Fri, 20 Feb 2009 14:13:41 +0100 2198659 http://www.medworm.com/index.php?rid=2015648&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19053167%26dopt%3DAbstract Authors: Uppaluri R, Dunn GP, Lewis JS The expanding and established literature that correlates tumor infiltrating lymphocytes (TILs) with outcomes of patients with solid tumors has contributed greatly to the appreciation of the interaction between the host immune system with neoplastic growth. This analysis has been limited to specific tumors, such as melanoma and ovarian cancer, and our understanding of TILs in relation to many other malignancies has yet to be explored. We review one less well studied malignancy, head and neck squamous cell carcinoma (HNSCC), and the initial attempts to examine the impact of TILs on outcomes of these patients. To provide a context for the discussion of TILs and HNSCC, we first review the epidemiology, relevant head and neck anatomy, immune responses ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=2015648 Sun, 07 Dec 2008 05:43:47 +0100 2015648 http://www.medworm.com/index.php?rid=1958718&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19006261%26dopt%3DAbstract Authors: Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T, Morishima T, Old LJ, Nakayama E The prostate cancer HERV-K gag-related NGO-Pr-54 antigen was identified by SEREX analysis using autologous patient serum. NGO-Pr-54 mRNA was observed to be faintly expressed in normal prostate and strongly expressed in a variety of cancers, including ovarian cancer (5/8), prostate cancer (6/9), and leukemia (5/14). A phage plaque assay showed that a strong reaction was constantly observed with clone ZH042 in which the 5' end of NGO-Pr-54 is deleted, suggesting that it contained the sequence coding for the protein product. A TI-35 mAb was produced using a recombinant protein (438 aa) deduced from the sequence of ZH042. Tran... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1958718 Sat, 15 Nov 2008 05:34:37 +0100 1958718 http://www.medworm.com/index.php?rid=1793513&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18783178%26dopt%3DAbstract Authors: Rubin B, Riond J, Courtiade L, Roullet N, Gairin JE Tumor cells and the immune system play a lethal "pas de deux" during tumor development. However, it is not clear which role the innate immune system plays in these interactions. We studied the interaction of normal spleen cells (NSCs) with tumor cells expressing low levels of MHCI on the cell surface. This interaction induces increased MHCI expression on the MHCI(low) tumor cells by a cell-cell contact-dependent, IFN-gamma-mediated mechanism. The effector cells responsible for the increased IFN-gamma production were identified as CD4+ CD1d-independent NKT cells, NK1.1+ NK cells and CD4+ CD11c+ DCs. The possible three cell collaboration is not activated by MHCI(high) tumor cells or normal fibroblasts. Kinetic experiments showe... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1793513 Tue, 16 Sep 2008 08:28:15 +0100 1793513 http://www.medworm.com/index.php?rid=1787855&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18783178%26dopt%3DAbstract Authors: Rubin B, Riond J, Courtiade L, Roullet N, Gairin JE Tumor cells and the immune system play a lethal "pas de deux" during tumor development. However, it is not clear which role the innate immune system plays in these interactions. We studied the interaction of normal spleen cells (NSCs) with tumor cells expressing low levels of MHCI on the cell surface. This interaction induces increased MHCI expression on the MHCI(low) tumor cells by a cell-cell contact-dependent, IFN-gamma-mediated mechanism. The effector cells responsible for the increased IFN-gamma production were identified as CD4+ CD1d-independent NKT cells, NK1.1+ NK cells and CD4+ CD11c+ DCs. The possible three cell collaboration is not activated by MHCI(high) tumor cells or normal fibroblasts. Kinetic experiments showe... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1787855 Sat, 13 Sep 2008 08:20:08 +0100 1787855 http://www.medworm.com/index.php?rid=1744938&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18752338%26dopt%3DAbstract Authors: Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, Oizumi S, Dosaka-Akita H, Nishimura M XAGE-1b is a cancer/testis antigen that has been shown to be expressed at a significant frequency and to be immunogenic in non-small cell lung cancer (NSCLC). In the present study, we investigated correlations between XAGE-1b expression and NSCLC patient survival. XAGE-1b expression was examined immunohistochemically using USO9-13, an anti-XAGE-1b monoclonal antibody, in 121 NSCLCs (83 adenocarcinomas and 38 other histological types). XAGE-1b expression was observed in 27 (32.5%) adenocarcinoma specimens. In the other histological types, positive staining was observed in only 1 specimen. HLA class I expression in these samples was assessed previously. XAGE-1b expression had no ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1744938 Sun, 31 Aug 2008 08:07:24 +0100 1744938 http://www.medworm.com/index.php?rid=1614519&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18613644%26dopt%3DAbstract In this study, HSP70 of both autologous and allogeneic origin was found to stimulate IFN-gamma production from peripheral blood mononuclear cells of CML patients, as well as of normal subjects. Further investigations demonstrated that the activity of HSP70 was dependent on both NK cells and dendritic cells (DCs). HSP70 did not induce significant IFN-gamma production from either NK cells or DCs alone. Mechanistically, we found that HSP70-mediated DC-NK cell crosstalk required cell-cell contact, which could be inhibited completely by neutralizing antibody against NK activating receptor NKG2D. The significance of NKG2D was further corroborated by the finding that HSP70 induced the expression of an NKG2D ligand, the MHC class I chain-related protein A (MICA), on DCs; HSP70-augmented IFN-gamma ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1614519 Sun, 13 Jul 2008 08:00:12 +0100 1614519 http://www.medworm.com/index.php?rid=1550134&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18581998%26dopt%3DAbstract Authors: Alves PM, Lévy N, Stevenson BJ, Bouzourene H, Theiler G, Bricard G, Viatte S, Ayyoub M, Vuilleumier H, Givel JC, Rimoldi D, Speiser DE, Jongeneel CV, Romero PJ, Lévy F Despite the high prevalence of colon cancer in the world and the great interest in targeted anti-cancer therapy, only few tumor-specific gene products have been identified that could serve as targets for the immunological treatment of colorectal cancers. The aim of our study was therefore to identify frequently expressed colon cancer-specific antigens. We performed a large-scale analysis of genes expressed in normal colon and colon cancer tissues isolated from colorectal cancer patients using massively parallel signal sequencing (MPSS). Candidates were additionally subjected to experimental evaluation ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1550134 Sat, 28 Jun 2008 16:00:22 +0100 1550134 http://www.medworm.com/index.php?rid=1515715&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18547033%26dopt%3DAbstract Authors: Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R We assessed the immunological status of stage III and IV head and neck squamous cell carcinoma (HNSCC) patients and age-matched healthy individuals. In HNSCC patients, the total leukocyte count was lower and the proliferating ability of PBMCs against phytohemagglutinin (PHA) was significantly downregulated. These cells showed lower expression of the early activation marker CD69. Within this PBMC population, the proportion of CD4+, CD8+ T cells, CD3- CD56+, CD16+ NK cells and CD3+ CD56+ NK-T cells was seriously downregulated. However, the proportion of CD4+ CD25+ Foxp3+ regulatory T cells having suppressor function was upregulated. Other immune cells, like CD14+ monocytes/macrophages and CD20+ B cells, were also fewer in numb... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1515715 Fri, 13 Jun 2008 20:37:01 +0100 1515715 http://www.medworm.com/index.php?rid=1471783&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18503261%26dopt%3DAbstract Authors: Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P The cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule on T cells acts to maintain homeostasis by regulating the proliferation of recently activated T cells. Blockade of CTLA-4 by anti-CTLA-4 antibody enhances T cell responses and has elicited significant tumor regression in some cancer patients. Clinical trials are ongoing to investigate the efficacy of anti-CTLA-4 antibody as a cancer therapeutic. Reports from several clinical trials have documented the occurrence of adverse events in patients treated with anti-CTLA-4 antibody which have some similarities with autoimmune conditions and have been termed immune-related adverse events (irAEs). Most irAEs are reversible with corticosteroid therapy. Some investigators s... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1471783 Wed, 28 May 2008 14:22:40 +0100 1471783 http://www.medworm.com/index.php?rid=1398746&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18433090%26dopt%3DAbstract Authors: Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM Cancer vaccines have been demonstrated to be a promising strategy for treating human neoplastic disease, but one of the limitations of these vaccines remains the paucity of target antigens to which to direct an effective immune response. We hypothesize that sperm fibrous sheath proteins may be a new class of useful antigens for developing successful cancer vaccines. This hypothesis is supported by the expression of two sperm fibrous sheath proteins, called sperm protein 17 and calcium-binding tyrosine-phosphorylation regulated protein, in tumors of unrelated histological origin and their capability to induce T cell-based immune responses. PMID: 18433090 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1398746 Fri, 25 Apr 2008 19:28:03 +0100 1398746 http://www.medworm.com/index.php?rid=1393348&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18426187%26dopt%3DAbstract Authors: Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ, Marie SK Medulloblastoma is the most common childhood malignant tumor of the central nervous system. Treatment of medulloblastoma requires harmful therapy and nevertheless carries a poor prognosis. Due to their presence in various cancers and their limited expression in normal tissues, CT antigens are ideal vaccine targets for tumor immunotherapy. CT antigens, such as MAGE and NY-ESO-1, have been employed in clinical trials in various malignancies but little is known about their presence in medulloblastoma. We analyzed 25 medulloblastomas for the expression of a panel of CT antigens by RT-PCR and immunohistochemistry. Messenger RNA expression in the samples was as follows: GAGE 64%, MAGEA3/6 56%, SYCP1... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1393348 Wed, 23 Apr 2008 19:45:03 +0100 1393348 http://www.medworm.com/index.php?rid=1333911&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18366150%26dopt%3DAbstract Authors: Voelter V, Pica A, Laurent J, Rimoldi D, Bouzourene H, Sajadi A, Matter M, Romero P, Rufer N, Speiser DE PMID: 18366150 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1333911 Fri, 28 Mar 2008 20:34:22 +0100 1333911 http://www.medworm.com/index.php?rid=1328465&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18363205%26dopt%3DAbstract Authors: PMID: 18363205 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1328465 Wed, 26 Mar 2008 21:22:51 +0100 1328465 http://www.medworm.com/index.php?rid=1324052&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18333603%26dopt%3DAbstract Authors: Old LJ The long-held hope that vaccination strategies might be effective against cancer has motivated numerous attempts over the past century to put the idea to test in the clinic. Although the generally disappointing results have cast a long shadow over the field, advances in cancer immunology growing on the remarkable insights from basic immunology provide a strong foundation and powerful new tools to guide current attempts to fashion effective cancer vaccines. This review covers the scientific basis and rationale for cancer vaccines, the challenges involved in assembling the many ingredients going into the construction of cancer vaccines, and the daunting obstacles confronting academic investigators wanting to transfer their discoveries into the clinical arena. The Cancer V... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1324052 Tue, 25 Mar 2008 13:03:36 +0100 1324052 http://www.medworm.com/index.php?rid=1270293&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18307280%26dopt%3DAbstract This study evaluates HLA gene expression and tumor infiltration by B-cells, macrophages, dendritic cells, T-helper and cytotoxic T-lymphocytes in response to short-term preoperative treatment with cyclooxygenase inhibitors. Patients with colorectal carcinoma were randomized to receive oral NSAID (indomethacin or celebrex) for three days preoperatively; controls received esomeprazol. Peroperative tumor biopsies and normal colon tissue were analyzed by microarray, quantitative PCR and immunohistochemistry. Efficacy of short-term systemic NSAID treatment was confirmed by measurement of PGE2 production in blood monocytes from healthy volunteers. NSAID treatment upregulated genes at the MHC locus on chromosome 6p21 in tumor tissue, but not in normal colon tissue, from the same patient. 23 of th... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1270293 Sat, 01 Mar 2008 20:08:43 +0100 1270293 http://www.medworm.com/index.php?rid=1244546&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18281925%26dopt%3DAbstract Authors: Jones HP, Wang YC, Aldridge B, Weiss JM In vitro measures of immune responsiveness toward tumors provide relevant information regarding the prevention and metastatic potential of cancer. In addition, the compartmentalization of immune responses is likely to be an important factor in dictating host antitumor immune responses. We have previously demonstrated that injection of antibody against B cells diminished pulmonary antitumor defenses. In the current study, we determined the effect of B cells on antitumor cellular responses against a lung metastatic tumor, MADB106. Lung B cells displayed sustained surface expression of CD80 and CD86, as compared to spleen B cells, in the presence of MADB106 tumor. Removal of B cells from lung lymphocyte cultures resulted in diminished IFN-g... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1244546 Wed, 20 Feb 2008 20:21:36 +0100 1244546 http://www.medworm.com/index.php?rid=1214688&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18251464%26dopt%3DAbstract We report here that mAb MX35 recognizes the sodium-dependent phosphate transport protein 2b (NaPi2b) in human cancer cells. This conclusion is based on several lines of experimental evidence, including 1) the identification of SLC34A2, the gene coding for NaPi2b, by immunoscreening an ovarian cancer cell line cDNA expression library with mAb MX35; 2) mass spectrometry sequencing of peptides obtained by fragmentation from mAb MX35 affinity-purified antigen, which show complete sequence homology to amino acid sequences in NaPi2b; 3) selective down-regulation of SLC34A2 gene expression by RNA interference and the resulting loss of mAb MX35 binding to MX35-expressing human cancer cells; and 4) the demonstration of specific mAb MX35 reactivity with recombinant fusion proteins and with synthetic... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1214688 Thu, 07 Feb 2008 20:18:49 +0100 1214688 http://www.medworm.com/index.php?rid=1196393&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18237105%26dopt%3DAbstract This study aims to analyze the expression of 14 cancer/testis (CT) antigens in multiple myeloma (MM) to identify possible prognostic markers and therapeutic targets. The expression of MAGEA1, MAGEA2, MAGEA3/6, MAGEA4, MAGEA10, MAGEA12, BAGE1, MAGEC1/CT7, the GAGE family, LAGE-1, PRAME, NY-ESO-1, SPA17 and SSX1 was studied by RT-PCR in 15 normal tissues, a pool of 10 normal bone marrow samples, 3 normal tonsils and bone marrow aspirates from 6 normal donors, 3 monoclonal gammopathies of undetermined significance (MGUS), 5 solitary plasmacytomas, 39 MM samples (95% advanced stage) and the MM cell line U266. MAGEC1/CT7 was expressed in bone marrow aspirates from one MGUS and one plasmacytoma. The frequencies at which CT antigen were found to be expressed in MM patients were MAGEC1/CT7 77%, LA... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1196393 Sat, 02 Feb 2008 20:05:37 +0100 1196393 http://www.medworm.com/index.php?rid=1160496&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18198818%26dopt%3DAbstract Authors: Saenger YM, Wolchok JD Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a negative regulator of T-cell mediated immune responses and is the target of new anti-tumor immunotherapy strategies. Ipilimumab is a fully human, antagonistic monoclonal antibody directed against CTLA-4. Results from preclinical and early clinical trials support current phase II/III testing of ipilimumab as first- and second-line therapy for metastatic melanoma. Ipilimumab promotes durable objective responses and/or stable disease in patients with metastatic melanoma. Adverse events are medically manageable, largely immune-related, and presumably linked to the drug's mechanism of action. As more patients are treated with ipilimumab, it is becoming clear that the kinetics of responses are heterogeneous and si... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1160496 Fri, 18 Jan 2008 21:20:54 +0100 1160496 http://www.medworm.com/index.php?rid=1113032&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18095639%26dopt%3DAbstract Authors: Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR Brother of the Regulator of Imprinted Sites (BORIS/CTCFL) is an autosomal cancer germline (CG) or cancer-testis antigen gene and paralog of CTCF that has been proposed to function as an oncogene in human cancer via dysregulation of the cancer epigenome. Here we show that genetic disruption of DNA methylation in human cancer cells induces BORIS expression, coincident with DNA hypomethylation and an altered histone H3 modification pattern at the BORIS promoter. Rapid amplification of cDNA ends (RACE) mapping revealed that the transcriptional start site of BORIS in human testis, DNMT deficient human cancer cells, and human epithelial ovarian cancer (EOC) tissues, is similar and lies within the 5' CpG island. The BORI... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1113032 Sun, 23 Dec 2007 01:00:02 +0100 1113032 http://www.medworm.com/index.php?rid=1108072&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18088084%26dopt%3DAbstract Authors: Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L Novel therapeutic agents that are safe and effective are needed for the treatment of pancreatic, ovarian, lung adenocarcinomas and mesotheliomas. Mesothelin is a glycosyl-phosphatidyl inositol (GPI)-linked membrane protein of 40 kDa over-expressed in all pancreatic adenocarcinoma and mesothelioma, in >70% of ovarian adenocarcinoma, and in non-small cell lung and colorectal cancers. The biological functions of mesothelin are not known, although it appears to be involved in cell adhesion via its interaction with MUC16. We have recently developed MORAb-009, a mouse-human chime... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1108072 Fri, 21 Dec 2007 01:12:54 +0100 1108072 http://www.medworm.com/index.php?rid=1011726&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17983203%26dopt%3DAbstract Authors: Silva WA, Gnjatic S, Ritter E, Chua R, Cohen T, Hsu M, Jungbluth AA, Altorki NK, Chen YT, Old LJ, Simpson AJ, Caballero OL Identification of genes that are upregulated in tumors, and whose normal expression excludes adult somatic tissues but includes germline and/or embryonic tissues, has resulted in a rich variety of cancer antigens that are attractive targets for cancer vaccine and other therapeutic approaches. In the present study, we extended this approach to include genes strongly and restrictively expressed in the placenta by mining publicly available SAGE and EST databases. We identified a number of genes with high expression in placenta and different cancer types but with relatively restricted expression in normal tissues. The gene with the most distinctive expression ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1011726 Thu, 08 Nov 2007 00:57:05 +0100 1011726 http://www.medworm.com/index.php?rid=1011725&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17983204%26dopt%3DAbstract Authors: Old LJ PMID: 17983204 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=1011725 Thu, 08 Nov 2007 00:57:05 +0100 1011725 http://www.medworm.com/index.php?rid=975881&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17948965%26dopt%3DAbstract Authors: Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, Ellis I, Durrant LG The MHC class I chain-related gene A (MICA) is frequently expressed on the surface of intestinal epithelium and by many epithelial tumours. MICA is a stress-induced antigen which was identified as an activator of natural killer cells via interaction with the NKG2D receptor. We have raised a rabbit polyclonal antibody against a synthetic peptide that recognises denatured MICA on both Western blots and in formalin-fixed paraffin-embedded sections. In the present study this antibody was used to undertake a definitive study of 530 breast cancer cases with mean follow up of 7 years to determine the prognostic significance of MICA expression. To detect any association between MICA expression and NK infi... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=975881 Thu, 25 Oct 2007 00:01:27 +0100 975881 http://www.medworm.com/index.php?rid=965618&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17944437%26dopt%3DAbstract Authors: Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnjatic S, Pan L, Hoffman E, Old LJ, Knuth A, Jäger E NY-ESO-1 is a cancer-testis antigen and an attractive target for immunotherapy in patients with different malignancies. Here we report the results of a phase I clinical study of intensive course NY-ESO-1 peptide vaccination, evaluating the safety, immunogenicity and clinical response in HLA-A2 positive patients with NY-ESO-1 expressing cancers. Of 20 patients enrolled in the trial, 14 completed at least 2 cycles of immunization and were evaluable for clinical and immunological response. Five of these evaluable patients were treated in cohort 1 (baseline seropositive) and 9 patients were treated in cohort 2 (baseline seronegativ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=965618 Sat, 20 Oct 2007 23:57:32 +0100 965618 http://www.medworm.com/index.php?rid=821837&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17715884%26dopt%3DAbstract Authors: Jungbluth AA, Silva WA, Iversen K, Frosina D, Zaidi B, Coplan K, Eastlake-Wade SK, Castelli SB, Spagnoli GC, Old LJ, Vogel M Besides their variable presence in fetal and adult germ cells, CT antigens have occasionally been detected in placental tissue. However, these data are scarce and solely based on mRNA analyses; nothing is known about their presence at the protein level. Here, we analyzed the expression of various CT antigens in placental tissues from gestational age week 5 to week 42 using monoclonal antibodies to various antigens of the MAGE-A and -C families, NY-ESO-1, as well as GAGE. We show that CT antigen expression in placenta varies widely for the various antigens, ranging from completely negative to abundant. Since little is known about the function and biology ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=821837 Sat, 25 Aug 2007 13:37:16 +0100 821837 http://www.medworm.com/index.php?rid=813425&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17705349%26dopt%3DAbstract In conclusion, repeated intravenous doses of up to 50 mg/m(2) of cG250 are safe. Furthermore cG250 has a long half-life and targets clear cell RCC effectively. PMID: 17705349 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=813425 Wed, 22 Aug 2007 00:23:23 +0100 813425 http://www.medworm.com/index.php?rid=813424&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17705350%26dopt%3DAbstract In conclusion, weekly cG250 with daily low-dose subcutaneous IL-2 is well tolerated. IL-2 does not influence cG250 biodistribution or increase HACA. PMID: 17705350 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=813424 Wed, 22 Aug 2007 00:23:23 +0100 813424 http://www.medworm.com/index.php?rid=807891&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17691714%26dopt%3DAbstract Authors: Dunn GP, Dunn IF, Curry WT Significant work in animal models combined with compelling studies in human patients together have begun to provide a higher resolution picture of how the immune system regulates cancer development. Currently, this immune system-tumor interaction is represented by the concept of cancer immunoediting, which emphasizes that immunity may subserve either classical cancer immunosurveillance functions or promote the eventual outgrowth of immunoevasive cancer cells. One important line of evidence supporting an immunosurveillance process in humans has been the finding that the presence of distinct profiles of TILs may be correlated with improved clinical outcomes in a subset of human cancers. However, the contribution of TILs to the natural history of glioma... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=807891 Mon, 20 Aug 2007 00:21:47 +0100 807891 http://www.medworm.com/index.php?rid=792180&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17625806%26dopt%3DAbstract In conclusion, NY-ESO-1 is more frequently expressed in metastatic than in primary MM and its expression is associated with thicker primary lesions and a higher frequency of metastatic disease, indicative of a worse prognosis. Our study suggests that patients with metastatic MM who express NY-ESO-1 may benefit from NY-ESO-1-based immunotherapy. PMID: 17625806 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=792180 Sat, 11 Aug 2007 00:00:35 +0100 792180 http://www.medworm.com/index.php?rid=732038&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17625806%26dopt%3DAbstract In conclusion, NY-ESO-1 is more frequently expressed in metastatic than in primary MM and its expression is associated with thicker primary lesions and a higher frequency of metastatic disease, indicative of a worse prognosis. Our study suggests that patients with metastatic MM who express NY-ESO-1 may benefit from NY-ESO-1-based immunotherapy. PMID: 17625806 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=732038 Sat, 14 Jul 2007 00:35:22 +0100 732038 http://www.medworm.com/index.php?rid=698852&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17591743%26dopt%3DAbstract Authors: Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P The idea of generating cytotoxic T-lymphocytes that have anti-tumor activity has been the focus of many clinical trials aimed at delivering effective immunotherapy to cancer patients. We have gained insight into the human immune system in cancer patients as a result of these numerous clinical investigations. It is now clear that although various vaccination methods are capable of inducing tumor antigen-specific T-cells in the circulating blood, these immunological responses are infrequently correlated with clinical responses. Therefore, it appears that priming of a T-cell response is not sufficient for tumor regression and other avenues, downstream of the priming phase, need to be investigated. Mechanisms of immune eva... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=698852 Wed, 27 Jun 2007 15:58:20 +0100 698852 http://www.medworm.com/index.php?rid=566603&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17441676%26dopt%3DAbstract In this study, we performed T cell immunomonitoring and analyzed tumor responses in these patients. To evaluate CD4 and CD8 T cell responses, an IFN-gamma secretion assay was used. The assay showed low background and was sensitive for detecting antigen-specific T cells. An increase in the CD4 T cell response was observed in 2 of 2 initially sero-positive and 5 of 7 initially sero-negative patients after vaccination. An increase in the CD8 T cell response was also observed in 2 of 2 sero-positive and 5 of 7 sero-negative patients after vaccination. Analysis of peptides recognized by CD4 and CD8 T cells revealed two dominant NY-ESO-1 regions, 73-114 and 121-144. Tumor responses were observed in 3 esophageal cancer patients and a malignant melanoma patient. In 3 of 4 prostate cancer patients,... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=566603 Tue, 24 Apr 2007 23:55:02 +0100 566603 http://www.medworm.com/index.php?rid=550455&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17388261%26dopt%3DAbstract Authors: Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, Warren BF, Piris J, Roncador G, Fox SB, Banham AH, Cerundolo V Recent results have shown a correlation between survival and frequency of tumour infiltrating T lymphocytes in colorectal cancer patients. However, it remains unclear whether the frequency of regulatory T cells is higher in colorectal cancer as compared to normal colon. To address this question we analysed the frequency and function of regulatory T cells in the peripheral blood and tumour infiltrating lymphocytes of colorectal cancer patients. The proportion of regulatory T cells in the peripheral blood of colorectal cancer patients (mean 8%) was significantly higher than that in normal controls (mean 2.2%). There were significantly more regulatory T c... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=550455 Wed, 18 Apr 2007 11:35:03 +0100 550455 http://www.medworm.com/index.php?rid=523857&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17394284%26dopt%3DAbstract Authors: Mandal-Ghosh I, Chattopadhyay U, Baral R An 85-kDa breast tumor associated antigen (BTAA) has been identified and partially characterized from human breast tumors. As BTAA is poorly immunogenic, enhancement of the anti-tumor immunity induced by BTAA is required to obtain an objective clinical response. The potent immune activation by an aqueous preparation of neem (Azadirachta indica) leaf (NLP) suggests its possible utility for enhancing immune responses to tumor vaccines. Mice (Swiss and Balb/c) and rats (Sprague Dawley) immunized with BTAA and NLP have a higher IgG antibody response and a lower IgM response than mice immunized with BTAA alone. Antibody generated by immunization with BTAA and NLP can induce antibody-dependent cellular cytotoxicity (ADCC) and cytotoxic T cell... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=523857 Fri, 06 Apr 2007 01:20:07 +0100 523857 http://www.medworm.com/index.php?rid=465336&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17335148%26dopt%3DAbstract In this study, we generated a XAGE-1b mAb, USO9-13. The B cell epitope recognized by the USO9-13 mAb was in the C-terminal region of the XAGE-1b protein and is also recognized by sera from patients with lung adenocarcinoma. Using USO9-13 and an anti-Flag mAb, we examined the translation products of the 4 transcripts. The XAGE-1a and b transcripts translated to the XAGE-1b protein. The XAGE-1c transcript possibly translated to 9- and 17-aa polypeptides. The XAGE-1d transcript translated to a protein consisting of 69 amino acids. Immunofluorescence analysis using USO9-13 mAb showed that the XAGE-1b protein is located in the nuclei of cells. Immunohistochemically, nuclear staining was heterogeneously observed in 25/47 lung adenocarcinomas, 1/12 hepatocellular carcinomas and 1/11 gastric cance... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=465336 Mon, 12 Mar 2007 01:30:04 +0100 465336 http://www.medworm.com/index.php?rid=465335&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17346028%26dopt%3DAbstract Authors: Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L The highly restricted distribution of human folate receptor-alpha (FRalpha) in normal tissues and its high expression in some tumors, along with its putative role in tumor cell transformation, make this antigen a suitable target for antigen-specific, monoclonal antibody-based immunotherapy for oncology indications. We have developed a therapeutic humanized monoclonal antibody with high affinity for FRalpha, named MORAb-003, which was derived from the optimization of the LK26 antibody using a whole cell genetic evolution platform. Here we show that MORAb-003 possesses novel, growth-inhibitory functions on cells overexpressing FRalpha... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=465335 Mon, 12 Mar 2007 01:30:04 +0100 465335 http://www.medworm.com/index.php?rid=434484&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17311362%26dopt%3DAbstract Authors: Odunsi K, Old LJ PMID: 17311362 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=434484 Sun, 25 Feb 2007 01:20:02 +0100 434484 http://www.medworm.com/index.php?rid=434483&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17311363%26dopt%3DAbstract Authors: Ohtani H Human colorectal cancer tissues are infiltrated by various immune/inflammatory cells, usually along the invasive margin. These responses tend be regarded as "non-specific". However, it is now clear that these cellular responses, particularly lymphocytic reactions, are independent prognostic factors for a better survival. Immunohistochemical subset analyses have generally disclosed that the number of T-lymphocytes is important. The effects of these T cells tend to be more manifest when the observation periods are longer. These data suggest that some degrees of anti-tumor immunity exist in human colorectal carcinomas. However, human tumors are generally composed of various histologic subtypes, which sometimes complicates these analyses and simple explanations may be mis... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=434483 Sun, 25 Feb 2007 01:20:02 +0100 434483 http://www.medworm.com/index.php?rid=410375&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17279610%26dopt%3DAbstract Authors: Souders NC, Sewell DA, Pan ZK, Hussain SF, Rodriguez A, Wallecha A, Paterson Y We have created a transgenic mouse with tissue-specific expression of the human papilloma virus (HPV) 16 E6 and E7 oncoproteins in the thyroid as a model of HPV transformed cancer. The expression of the transgenes results in the formation of palpable thyroid tumors. E7 is not expressed in other tissues but is expressed in medullary thymic epithelial cells, which have been implicated in the control of negative selection. We show that Listeria-based vaccines against E7 can induce the regression of solid implanted tumors in the transgenic mice, although at a lower frequency than in wild type (WT) mice. E7-specific CD8+ T cells induced in transgenic mice are of both lower avidity and lower frequency whe... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=410375 Mon, 12 Feb 2007 14:40:03 +0100 410375 http://www.medworm.com/index.php?rid=374798&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17217256%26dopt%3DAbstract Authors: Nelson PT, Zhang PJ, Spagnoli GC, Tomaszewski JE, Pasha TL, Frosina D, Caballero OL, Simpson AJ, Old LJ, Jungbluth AA Cancer/testis (CT) antigens are named after their expression pattern as they are typically present in various types of tumors and in the germ cells of normal adult testis. Adult ovarian tissue is usually reported to be CT antigen negative. Based on the differences in female versus male gonadal development, the ovarian counterpart of the most predominant CT antigen positive testicular germ cells are not prevalent in the adult ovary. Hence, we analyzed the protein expression of several CT antigens in fetal ovary by immunohistochemistry with various monoclonal antibodies (mAbs) previously generated by our group. The mAbs used were: MA454 (MAGE-A1), M3H67 (MAGE-A3)... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=374798 Tue, 23 Jan 2007 04:45:03 +0100 374798 http://www.medworm.com/index.php?rid=303623&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17137291%26dopt%3DAbstract This study identified NY-ESO-1 (CT6) as a MAGE-C1 binding partner. Immunoprecipitation and immunofluorescence staining confirmed MAGE-C1 interaction with NY-ESO-1, and cytoplasmic co-localization of both proteins in melanoma cells. Co-expression of these two genes was found to occur in cancer cell lines from different origins, as well as in primary tumors (multiple myeloma and non-small cell lung cancer samples). This is the first report of direct interaction between two CT antigens and may be pertinent in the light of the frequently coordinated expression of these proteins. PMID: 17137291 [PubMed - in process] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=303623 Sun, 03 Dec 2006 08:19:02 +0100 303623 http://www.medworm.com/index.php?rid=257320&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17073402%26dopt%3DAbstract Authors: Hicks AM, Willingham MC, Du W, Pang CS, Old LJ, Cui Z SR/CR (spontaneous regression/complete resistance) mice resist multiple types of cancer cells injected at numbers that are lethal to wild type (WT) mice. When the anti-tumor response was examined, leukocytes of the innate immune system, including neutrophils (PMN), macrophages and NK cells, infiltrated the tumor site for a multipronged killing response. Each cell type had independent killing activity against the cancer cells. A second aspect of this multipronged response was that cancer cells could be killed either via necrosis in vivo or via apoptosis by purified macrophages. Lymphoid cells displayed perforin (pfp) and granzymes (gzm) as effector molecules, but macrophages produced reactive oxygen species (ROS) and secrete... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=257320 Wed, 01 Nov 2006 18:32:02 +0100 257320 http://www.medworm.com/index.php?rid=133353&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16875435%26dopt%3DAbstract Authors: Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin-Chesa P Endosialin is a C-type lectin-like cell surface receptor of unknown function, with a distinctive pattern of endothelial expression in newly formed blood vessels in human cancers. The murine orthologue of endosialin has been identified, opening up the analysis of developmental regulation in the embryo and in aberrant tissue remodeling, notably cancer angiogenesis. To advance these studies we have generated an antibody to the extracellular domain of mouse endosialin and mapped protein expression from embryonic day E10.0 to the adult stage, complemented by mRNA quantification and co-typing for standard endothelial markers. Four main findings emerged. First, endosialin protein is restricted to vascul... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=133353 Wed, 02 Aug 2006 16:46:02 +0100 133353 http://www.medworm.com/index.php?rid=109400&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16401063%26dopt%3DAbstract Authors: Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG Tumor vaccines represent one type of molecularly targeted therapy being investigated for the treatment of prostate cancer. Although many prostate-specific proteins are being tested as target antigens for prostate cancer vaccines, most are not natural targets of an immune response in patients with cancer. Using sera from cancer patients, several research groups have identified a large family of immunologically recognized proteins whose expression is normally confined to immune-privileged testis tissue but which may be expressed in cancers of different histological origins. These proteins, so-called cancer-testis (CT) antigens, are appealing targets for immune-based therapies because they are essentially tumor-restricted antigens an... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109400 Tue, 18 Jul 2006 23:50:20 +0100 109400 http://www.medworm.com/index.php?rid=109399&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16405301%26dopt%3DAbstract Authors: Scanlan MJ, Ritter G, Yin BW, Williams C, Cohen LS, Coplan KA, Fortunato SR, Frosina D, Lee SY, Murray AE, Chua R, Filonenko VV, Sato E, Old LJ, Jungbluth AA To identify novel, tissue-restricted cell surface proteins in cancer which can serve as targets for antibody-based diagnostics and therapeutics, a translated version of the expressed sequence tag database (tblastn) was mined for transcripts with similarity to the glycoprotein A33 (GPA33) colon cancer antigen. A novel human transcript, termed A34, was identified which encoded a putative cell surface protein, GPA34, which is approximately 30% identical to GPA33 and other members of the junctional adhesion molecule (JAM) family. Conventional end-point and quantitative real-time RT-PCR showed that A34 mRNA expression is highl... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109399 Tue, 18 Jul 2006 23:50:20 +0100 109399 http://www.medworm.com/index.php?rid=109398&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16457586%26dopt%3DAbstract Authors: PMID: 16457586 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109398 Tue, 18 Jul 2006 23:50:20 +0100 109398 http://www.medworm.com/index.php?rid=109397&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16468707%26dopt%3DAbstract Authors: Watanabe Y, LePage S, Elliott M, Secrist H, Tanaka T, Kawahara M, Matsumura A, Hosoe S, Ogawara M, Okada M, Repasky B, Sleath P, Wang T, Henderson R In order to establish a rationale for immunotherapy for lung cancer, we have investigated immunological characteristics of tumor-associated antigens (TAAs) discovered through molecular approaches. Preexisting Abs specific to these predicted TAAs were examined using specimens of lung pleural effusions (LPEs) and sera in non-small cell lung cancer (NSCLC) patients. The novel cancer-testis (CT) antigens L514S and L552S were highly expressed in approximately half of the NSCLC tissues and established cell lines examined. When lung cancer patients in the USA and Japan were screened, 13%, 17%, and 5% were found to have Abs specific to re... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109397 Tue, 18 Jul 2006 23:50:20 +0100 109397 http://www.medworm.com/index.php?rid=109396&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16483188%26dopt%3DAbstract Authors: Schanzer JM, Baeuerle PA, Dreier T, Kufer P Pro-inflammatory cytokines regulate the growth, differentiation, and activation of immune cells and can play a role in antitumor responses. GM-CSF and IL-2 induce tumor rejection in animal models when expressed by tumor cells, and IL-2 is used for the treatment of melanoma and renal cell cancer. However, high doses of GM-CSF and IL-2 are associated with severe side effects in cancer patients. We generated a dual cytokine fusion protein for simultaneous targeted delivery of human GM-CSF and IL-2 to human tumors. The fusion protein is based on a heterodimeric core structure formed by human CH1 and C kappa domains (heterominibody) with C-terminally fused human cytokines and N-terminally fused human single-chain Ab fragments (scFv) speci... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109396 Tue, 18 Jul 2006 23:50:20 +0100 109396 http://www.medworm.com/index.php?rid=109395&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16524255%26dopt%3DAbstract Authors: O'Boyle KP, Coatsworth S, Anthony G, Ramirez M, Greenwald E, Kaleya R, Steinberg JJ, Dutcher JP, Wiernik PH Resected carcinoma patients were immunized 3-5 times with ovine submaxillary gland mucin (OSM) containing predominantly sialylated Tn (sTn), completely desialylated ovine submaxillary gland mucin (dOSM) containing predominantly Tn, or 50% desialylated OSM containing Tn and sTn plus bacillus Calmette-Guerin (BCG) as an immunologic adjuvant. Pre- and postimmunization sera were quantified by ELISA, whole-cell ELISA, and immune stain dot blots. Fifteen of 17 patients produced IgG antibody titers from 40 to 5120 times more reactive with OSM and dOSM postimmunization. More importantly, these IgG antibodies reacted with LS-174T, a human colon carcinoma cell line. Significant DT... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109395 Tue, 18 Jul 2006 23:50:20 +0100 109395 http://www.medworm.com/index.php?rid=109394&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16551058%26dopt%3DAbstract Authors: Lejeune FJ, Liénard D, Matter M, Rüegg C Recombinant human tumour necrosis factor (TNF) has a selective effect on angiogenic vessels in tumours. Given that it induces vasoplegia, its clinical use has been limited to administration through isolated limb perfusion (ILP) for regionally advanced melanomas and soft tissue sarcomas of the limbs. When combined with the alkylating agent melphalan, a single ILP produces a very high objective response rate. In melanoma, the complete response (CR) rate is around 80% and the overall objective response rate greater than 90%. In soft tissue sarcomas that are inextirpable, ILP is a neoadjuvant treatment resulting in limb salvage in 80% of the cases. The CR rate averages 20% and the objective response rate is around 80%. The mode of action ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109394 Tue, 18 Jul 2006 23:50:20 +0100 109394 http://www.medworm.com/index.php?rid=109393&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16594646%26dopt%3DAbstract Authors: Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y, Chen LH, Ouyang WM, Xu XG, Jian JL, Güre AO, Fortunato S, Ritter G, Old LJ, Simpson AJ, Chen YT, Jin B, Jungbluth AA CT10/MAGE-C2 is a recently identified antigen that, typically of cancer/testis (CT) antigens, can be found in various malignant tumors and in normal adult testis. As with many other CT antigens, our knowledge is based mainly on mRNA expression data. In the present study, we describe the generation of mAbs to CT10/MAGE-C2 for the analysis of its protein expression. Newly generated clones were chosen based on their reactivity in ELISA, immunoblotting, and immunohistochemistry (IHC). Emphasis was put on the reactivity of newly generated reagents on formalin-fixed, paraffin-embedded tissue to ensure their applicability to ar... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109393 Tue, 18 Jul 2006 23:50:20 +0100 109393 http://www.medworm.com/index.php?rid=109392&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16626110%26dopt%3DAbstract Authors: Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ Antitumor immune responses can be elicited in preclinical mouse melanoma models using plasmid DNA vaccines encoding xenogeneic melanosomal differentiation antigens. We previously reported on a phase I clinical trial of human tyrosinase (huTyr) DNA vaccination of 9 dogs with advanced malignant melanoma (World Health Organization stages II-IV), in which we demonstrated the safety of the treatment and the prolongation of the expected survival time (ST) of subjects as compared to historical, stage-matched controls. As a secondary goal of the same study, we report here on the induction of tyrosinase-specific antibody responses in three of the nine dogs vaccinated with huTyr DNA. The antibodies in tw... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109392 Tue, 18 Jul 2006 23:50:20 +0100 109392 http://www.medworm.com/index.php?rid=109391&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D16808432%26dopt%3DAbstract Authors: Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M The E6 and E7 proteins of high-risk human papillomavirus (HPV) types are thought to be the ideal sources of antigens for immunotherapy for cervical cancer since they are expressed by the tumors and not by normal cells. We recently described new HPV 16 epitopes, including the E6 52-61 peptide restricted by HLA class I molecule B57. Primary tumor cell lines were established from three HLA-B57 positive, HPV 16 positive cervical cancer patients, and their recognition by a E6 52-61 specific CD8+ T cell clone was determined using a chromium release assay and an IFN-gamma enzyme-linked immunospot (ELISPOT) assay. The recognition of homologous epitopes contained in other high-risk HPV types (18, 31, 33, 35, 39, 45, 51, 52... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109391 Tue, 18 Jul 2006 23:50:20 +0100 109391 http://www.medworm.com/index.php?rid=109408&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15755075%26dopt%3DAbstract In this study, we have further characterized T cells derived from vaccine-infiltrating lymphocyte (VIL) responses. We found that the infiltrates capable of producing IFN-gamma and cytolytic activity could recognize vaccine peptide, as well as antigen-positive melanoma cells. We studied antigen-specific T cell responses from VILs and peripheral blood in 10 patients who participated in a clinical trial. All patients received systemic Flt3 ligand (20 microg/kg/d) and i.d. peptides: Three NY-ESO-1 peptides, SLLMWITQCFL (157-167), SLLMWITQC (157-165), QLSLLMWIT (155-163); tyrosinase internal peptide YMDGTMSQV (368-376); Melan-A/MART-1 analogue peptide ELAGIGILTV (26-35, E27L substitution); and influenza matrix peptide GILGFVFTL (58-66). In 54 paired VIL and peripheral blood analyses, a good cor... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109408 Wed, 09 Mar 2005 07:00:00 +0100 109408 http://www.medworm.com/index.php?rid=109409&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15745419%26dopt%3DAbstract Authors: Segal NH, Blachere NE, Shiu HY, Leejee S, Antonescu CR, Lewis JJ, Wolchok JD, Houghton AN Serological analysis of recombinant cDNA libraries (SEREX) uses high titer IgGs to identify antigens expressed by autologous cancers. In order to identify tumor antigens in soft tissue sarcoma (STS), sera from four patients with malignant fibrous histiocytoma (MFH), gastrointestinal stromal tumor (GIST), pleomorphic liposarcoma, and dedifferentiated liposarcoma were screened against cDNA libraries derived from autologous tumor. We identified 18 antigens encoded by 15 different genes, including DLG7, which is located on chromosome 14q22, a locus previously found to be altered in STS, and the proto-oncogene JUN. Ten of fourteen antigens (71%) do not react with sera from healthy donors, sugg... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109409 Fri, 04 Mar 2005 07:00:00 +0100 109409 http://www.medworm.com/index.php?rid=109410&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15723450%26dopt%3DAbstract Authors: Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, Smyth FE, Lee FT, Cebon J, Davis ID, Hopkins W, Mountain AJ, Rigopoulos A, Hanai N, Old LJ We conducted an open label dose-escalation phase I trial of chimeric anti-GD3 mAb KM871 in patients with metastatic melanoma. Patients were entered into one of five dose levels (1, 5, 10, 20, and 40 mg/m2) and received three infusions of KM871 at 2-wk intervals. A metastatic melanoma site was biopsied at day 7-10. Pharmacokinetics, immune function, and mechanism of action of KM871 were analysed. A total of 17 patients were entered into the trial; 15 were evaluable. KM871 had a serum half-life (T1/2-beta) based on ELISA of 10.39 +/- 1.12 d (mean +/- SD). Trough levels >1.0 microg/mL KM871 at 2 wk postinfusion were seen with the 10 mg/m2... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109410 Tue, 22 Feb 2005 07:00:00 +0100 109410 http://www.medworm.com/index.php?rid=109411&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15683221%26dopt%3DAbstract In this study, we exploit oligonucleotide technology to identify genes in melanoma and soft tissue sarcoma (STS) that display a cancer-testis/GCA expression profile. We identified 59 such genes, including GCAs we knew to be recognized by T lymphocytes. Among our findings are the expression of PRAME in monophasic synovial sarcoma, PRAME and NY-ESO-1 in myxoid/round cell liposarcoma, and SSX2 and members of the GAGE family in malignant fibrous histiocytoma. Furthermore, the proto-oncogene DBL/MCF2 was identified as encoding a novel candidate GCA expressed by clear cell sarcoma/melanoma of soft parts (MSP). DBL/MCF2 peptides that are bound to HLA-A*0201 were identified and recognized by T lymphocytes. These results show the utility of high-throughput expression analysis in the efficient scree... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109411 Tue, 01 Feb 2005 07:00:00 +0100 109411 http://www.medworm.com/index.php?rid=109412&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15641767%26dopt%3DAbstract Authors: Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S, Mincheff M Prostate-specific membrane antigen (PSMA), whose expression is upregulated in poorly differentiated, metastatic, and hormone refractory prostate cancer, could be targeted by gene-based vaccines. The aim of this study was to characterize the humoral immune response against PSMA in prostate carcinoma patients who have been vaccinated against PSMA with gene-based vaccines. Sera from prostate cancer patients who had been immunized repeatedly with plasmid DNA and a recombinant adenoviral vector, both carrying an expression cassette for human PSMA, and sera from healthy donors were tested for anti-PSMA antibodies by Western blot analysis and immunofluorescence. PSMA-producing LNCaP cells, recombinan... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109412 Tue, 11 Jan 2005 07:00:00 +0100 109412 http://www.medworm.com/index.php?rid=109413&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15603546%26dopt%3DAbstract Authors: Hasegawa K, Koizumi F, Noguchi Y, Hongo A, Mizutani Y, Kodama J, Hiramatsu Y, Nakayama E The SSX genes are members of the cancer-testis (CT) antigen family. SSX2, the prototype SSX gene, was found by serological analysis of antigens by recombinant expression cloning (SEREX). Since little is known about SSX expression in gynecological malignancies, we investigated SSX mRNA expression in 115 gynecological cancer specimens and 25 normal control samples by RT-PCR. We also tested the humoral immune response to SSX2 and SSX4 using recombinant proteins. We found relatively high SSX4 mRNA expression in endometrial cancer (24%), ovarian cancer (13%), and cervical cancer (20%). In contrast, SSX1 and SSX2 mRNA expression was detected in not more than 4% of the gynecological cancer specim... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109413 Fri, 17 Dec 2004 07:00:00 +0100 109413 http://www.medworm.com/index.php?rid=109414&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15600300%26dopt%3DAbstract Authors: Huarte E, Karbach J, Gnjatic S, Bender A, Jäger D, Arand M, Atanackovic D, Skipper J, Ritter G, Chen YT, Old LJ, Knuth A, Jäger E NY-ESO-1 is one of the most immunogenic cancer antigens known to date, eliciting spontaneous immune responses in approximately 50% of patients with NY-ESO-1+ cancers. Spontaneous CD4+ and CD8+ T cell responses were found in patients with detectable NY-ESO-1 serum antibody, indicating an integrated type of immune response induced by NY-ESO-1+ malignancies. A close association between spontaneous NY-ESO-1 immunity and the HLA-DP4 allele was suggested in a recent study. To address these results, we assessed the NY-ESO-1 antibody and HLA-DP4 status of 102 patients with NY-ESO-1+ malignancies. However, no correlation between HLA-DP4 and NY-ESO-1 immuni... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109414 Thu, 16 Dec 2004 07:00:00 +0100 109414 http://www.medworm.com/index.php?rid=109415&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15563124%26dopt%3DAbstract Authors: Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M About 15% of all human colorectal, gastric, and endometrial tumors, and the majority of tumors in patients suffering from hereditary nonpolyposis colorectal cancer syndrome, are caused by loss of DNA mismatch repair functions. In the affected cancer cells, this results in insertion or deletion mutations at short, repetitive DNA sequences referred to as microsatellites. Such mutations in coding microsatellites (cMS) cause translational frameshifts that may destroy gene function. These frameshift mutations could also cause the translation of immunogenic neopeptides at the carboxy terminus. Several such mutations have been identified recently. However, since none of the frameshift-induced neopeptides ident... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109415 Thu, 25 Nov 2004 07:00:00 +0100 109415 http://www.medworm.com/index.php?rid=109416&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15546177%26dopt%3DAbstract Authors: Lee SY, Williamson B, Caballero OL, Chen YT, Scanlan MJ, Ritter G, Jongeneel CV, Simpson AJ, Old LJ Serological analysis of recombinant cDNA expression libraries (SEREX) has led to the identification of many of the antigens recognized by the immune system of cancer patients, which are collectively referred to as the cancer immunome. We used SEREX to screen a testicular cDNA expression library with sera obtained from non-small cell lung cancer patients and isolated cDNA clones for 82 antigens. These included a total of 31 antigens previously identified by SEREX, and 51 that did not match entries in the Cancer Immunome Database and were considered newly identified antigens. Overall, the antigens comprised 62 known proteins and 20 uncharacterized gene products. Six antigens (NY-T... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109416 Wed, 17 Nov 2004 07:00:00 +0100 109416 http://www.medworm.com/index.php?rid=109417&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15521719%26dopt%3DAbstract Authors: Qian F, Gnjatic S, Jäger E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood A, Old LJ, Odunsi K The NY-ESO-1 antigen is expressed in a significant proportion of patients with epithelial ovarian cancer (EOC) and appears to be an ideal target for immunotherapy. In order to elucidate the nature of the HLA-DPB1*0401/0402 (DP4+)-restricted CD4+ immune response in patients with NY-ESO-1-expressing EOC, peripheral blood CD4+ T cells from HLA-DP4+ patients were stimulated with the NY-ESO-1 epitope 157-170 and tested for the release of type 1 (IFN-gamma) and type 2 (IL-5) cytokines in enzyme-linked immunospot assays. Of 14 DP4+ EOC patients who tested seronegative for NY-ESO-1, 3 patients had a detectable CD4+ T cell response to NY-ESO-1 epi... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109417 Wed, 03 Nov 2004 07:00:00 +0100 109417 http://www.medworm.com/index.php?rid=109418&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15516106%26dopt%3DAbstract Authors: Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT, Jungbluth AA, Gnjatic S, Santiago D, Ritter G, Chen WF, Old LJ, Ji JF Gastric cancer has the highest mortality rate and the second-highest morbidity rate of all malignant tumors in China. Since cancer/testis (CT) antigens are expressed in various types of human tumors but generally not in normal tissue except for testis, they are promising antigens for cancer immunotherapy. NY-ESO-1, in particular, is the most immunogenic of the CT antigens. To study the feasibility of developing a CT antigen vaccine for gastric cancer, 101 gastric cancer samples were analyzed for the presence of NY-ESO-1 mRNA and that of 10 other CT antigen genes. Twelve out of 101 samples (11.9%) were found to be NY-ESO-1 mRNA-positive, 11 of them from advanced stage... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109418 Mon, 01 Nov 2004 07:00:00 +0100 109418 http://www.medworm.com/index.php?rid=109419&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15487888%26dopt%3DAbstract Authors: Tammela J, Jungbluth AA, Qian F, Santiago D, Scanlan MJ, Keitz B, Driscoll D, Rodabaugh K, Lele S, Old LJ, Odunsi K SCP-1 is a novel tumor antigen that belongs to the growing family of cancer/testis (CT) antigens, and it is a potential target for immunotherapy. In an effort to determine the expression of SCP-1 in epithelial ovarian cancer (EOC), one-step RT-PCR was performed with RNA from epithelial ovarian tumor tissues and with two normal ovarian surface epithelial cell lines. We used immunohistochemistry (IHC) to investigate SCP-1 expression in paraffin-fixed EOC samples and ELISA to test sera from a subgroup of patients for SCP-1 antibody. SCP-1 was expressed in 15 out of 100 (15%) primary tumors, as determined by RT-PCR. The normal ovarian surface epithelial cell lines we... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109419 Mon, 18 Oct 2004 06:00:00 +0100 109419 http://www.medworm.com/index.php?rid=109420&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15384929%26dopt%3DAbstract Authors: Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J Dendritic cells (DCs) show promise as adjuvants in anticancer immunotherapeutic strategies. Flt3 ligand (FL) is a hematopoietic growth factor that increases the number of immature DCs in the blood and other tissues. We treated 27 patients with metastatic or high-risk resected melanoma with s.c. FL daily for 14 d in three 28 d cycles. Eighteen of these patients also received vaccination with influenza (Flu), Melan-A (Mel), tyrosinase (Tyr), and NY-ESO-1 peptides. To induce local DC maturation, 8 of the vaccinated patients had imiquimod, a Toll-like receptor-7 ligand (TLR7L), applied topically to their vaccine sites. Patients were... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109420 Thu, 23 Sep 2004 06:00:00 +0100 109420 http://www.medworm.com/index.php?rid=109421&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15327279%26dopt%3DAbstract Authors: Baj-Krzyworzeka M, Baran J, Szatanek R, Stankiewicz D, Siedlar M, Zembala M Upon contact with tumor cells when cocultured in vitro, human monocytes become unresponsive (deactivated) to restimulation and demonstrate decreased production of TNF-alpha and IL-12, and enhanced IL-10 secretion. The present study was undertaken to determine whether immunomodulatory agents (proinflammatory cytokines and PPD of tuberculin) could either prevent or reverse the deactivation of monocytes. Monocytes were treated with the agents either before or after being cocultured with tumor cells. Pretreatment of monocytes with IFN-gamma, either alone or in combination with TNF-alpha, GM-CSF, or PPD, significantly enhanced TNF-alpha and IL-12 production by deactivated monocytes. TNF-alpha, GM-CSF, and P... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109421 Wed, 25 Aug 2004 06:00:00 +0100 109421 http://www.medworm.com/index.php?rid=109422&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15298487%26dopt%3DAbstract Authors: Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D Sarcomas are rare but aggressive malignant tumors associated with high mortality, for which the efficacy of standard therapies remains limited. In order to develop immunotherapeutic approaches for the treatment of sarcoma, we studied the relevance of cancer/testis antigens (CTAs), a group of antigens whose expression is developmentally regulated and that is specifically found in some tumor types, as sarcoma vaccine targets. CTA expression was assessed by PCR and/or immunohistochemistry (IHC) in sarcoma tumor samples that included different histological subtypes and sarcoma cell lines. Expression of HLA class I was assessed by IHC in tumor samples and by FACS anal... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109422 Mon, 09 Aug 2004 06:00:00 +0100 109422 http://www.medworm.com/index.php?rid=109423&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15270555%26dopt%3DAbstract Authors: McCarthy BA, Mansour A, Lin YC, Kotenko S, Raveche E RNA interference, or RNAi, is designed to work by Watson-Crick base pairing and to result in a posttranscriptional block in protein synthesis. Antiapoptotic proteins are a major focus of cancer therapy and make attractive targets for RNAi. An IL-10 RNAi sequence was designed in accordance with Tuschl rules and was modeled to a hairpin configuration. In chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world, the failure to undergo apoptosis may be responsible for the accumulation of malignant B-1 cells. Interleukin-10, despite controversy, has been shown to have antiapoptotic properties, and increased endogenous IL-10 production has been found in CLL by several labs. A malignant B-1 cell line, LNC, ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109423 Fri, 23 Jul 2004 06:00:00 +0100 109423 http://www.medworm.com/index.php?rid=109424&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15255672%26dopt%3DAbstract Authors: Vaughan HA, St Clair F, Scanlan MJ, Chen YT, Maraskovsky E, Sizeland A, Old LJ, Cebon J Learning to identify tumor and tumor-associated antigens in patients with squamous cell carcinoma of the head and neck (HNSCC) may bring about better diagnostic and prognostic evaluations of the disease, innovative therapies based on immunological approaches, and a better understanding of the biology of tumorigenesis. Serological analysis of tumor antigens by recombinant cDNA expression cloning (SEREX) has been used to identify antigens in head and neck cancer to which patients have produced high-titered IgG antibodies. Four cDNA expression libraries have been screened with sera from 6 head and neck cancer patients. Thirty-seven individual gene products were identified. Thirty-one previousl... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109424 Fri, 16 Jul 2004 06:00:00 +0100 109424 http://www.medworm.com/index.php?rid=109425&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15149168%26dopt%3DAbstract Authors: Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE The purpose of this study was to test melanoma vaccines consisting of peptides and immunological adjuvants for optimal immunogenicity and to evaluate laboratory immune monitoring for in vivo relevance. Forty-nine HLA-A2 positive patients with Melan-A positive melanoma were repeatedly vaccinated with Melan-A peptide, with or without immune adjuvant AS02B (QS21 and MPL) or IFA. Peptide-specific CD8 T cells in PBLs were analyzed ex vivo using fluorescent HLA-A2/Melan-A multimers and IFN-gamma ELISPOT assays. The vaccines were well tolerated. In vivo expansion of Melan-A-specific CD8 T cells w... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109425 Wed, 19 May 2004 06:00:00 +0100 109425 http://www.medworm.com/index.php?rid=109426&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15086273%26dopt%3DAbstract Authors: Staib F, Distler M, Bethke K, Schmitt U, Galle PR, Heike M Heat shock proteins (HSPs) have two unique roles as constituents of tumor vaccines: (i) to shuttle associated tumor antigens into professional antigen-presenting cells (APCs) and (ii) to activate professional APCs. Here we investigated the shuttle function of the HSP gp96 (glycoprotein 96) for a human melanoma peptide antigen MART-1 that was noncovalently bound to gp96 in vitro. This in vitro complexing reaction was optimized using the radioiodinated MART-1 peptide and human gp96. Up to 20% of gp96 molecules could bind the peptide, assuming a 1:1 molar ratio. The binding was temperature-dependent and thus reversible. At -20 degrees C, 95% of the peptide remained complexed after 24 h, but 25% and 60% of the peptide diss... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109426 Fri, 16 Apr 2004 06:00:00 +0100 109426 http://www.medworm.com/index.php?rid=109429&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14871062%26dopt%3DAbstract This study shows that HERV families are more widely expressed than originally thought and that some members of the HERV-K and -H families could encode targets for cancer immunotherapy. PMID: 14871062 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109429 Wed, 11 Feb 2004 07:00:00 +0100 109429 http://www.medworm.com/index.php?rid=109430&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14738373%26dopt%3DAbstract Authors: Scanlan MJ, Simpson AJ, Old LJ Cancer/testis (CT) antigens are immunogenic in cancer patients, exhibit highly tissue-restricted expression, and are considered promising target molecules for cancer vaccines. To date, 44 CT gene families have been identified and their expression studied in numerous cancer types. For example, bladder cancer, non-small cell lung cancer, and melanoma are high CT gene expressors, with 11/20 (55%), 17/33 (51%) and 17/32 (53%) of the CT transcripts examined by RT-PCR detected in 20% or more of the specimens examined, respectively. Breast and prostate cancer can be considered moderate CT gene expressors, with 12/32 (37%) and 6/20 (30%) CT transcripts having an expression frequency >20%, respectively, while renal and colon cancer are low CT gene expr... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109430 Fri, 23 Jan 2004 07:00:00 +0100 109430 http://www.medworm.com/index.php?rid=109431&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14680360%26dopt%3DAbstract Authors: Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Old LJ Cancer-testis (CT) antigens are ideal vaccine targets since their expression is restricted in adult tissues to testicular germ cells and a subset of cancers. The frequency of expression in transitional cell carcinomas (TCCs) of NY-ESO-1, the most immunogenic CT antigen to date, and its closely related gene LAGE-1 was studied. NY-ESO-1 and LAGE-1 antigen expression were found to occur frequently in high-grade TCC tumors. On an MSKCC IRB-approved protocol, 68 patient specimens were collected prospectively at the time of transurethral resection or cystectomy, of which 43 were read pathologically as high-grade tumors (pCIS, pTaG3, pT1, pT2, ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109431 Thu, 18 Dec 2003 07:00:00 +0100 109431 http://www.medworm.com/index.php?rid=109432&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14677925%26dopt%3DAbstract Authors: Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M HOM-MEL-40/SSX2 is a SEREX-defined cancer testis antigen with frequent expression in various human neoplasms. To search for HLA-A*0201 restricted peptides that induce HOM-MEL-40/SSX2-specific CD8+ responses in breast cancer patients, we used the SYFPEITHI algorithm to identify three HOM-MEL-40/SSX2-derived nonamers with high binding affinity for HLA-A*0201, which has a prevalence of 40% in the Caucasian population. Of the three peptides, p41-49 and p103-111 but not p167-175 had been shown to be processed by the proteasome. Only stimulation with p103-111 induced HOM-MEL-40-specific CTLs in 5/7 patients with HOM-MEL-40/SSX2 positive breast cancers and in 6/11 ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109432 Wed, 17 Dec 2003 07:00:00 +0100 109432 http://www.medworm.com/index.php?rid=109433&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14670032%26dopt%3DAbstract Authors: PMID: 14670032 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109433 Fri, 12 Dec 2003 07:00:00 +0100 109433 http://www.medworm.com/index.php?rid=109427&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15022367%26dopt%3DAbstract Authors: Old LJ PMID: 15022367 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109427 Fri, 12 Dec 2003 07:00:00 +0100 109427 http://www.medworm.com/index.php?rid=109434&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14664500%26dopt%3DAbstract We report here the identification of a new MAGE-6 antigenic peptide, which is recognized by a tumor-specific cytolytic T lymphocyte clone isolated from a melanoma patient. The peptide, ISGGPRISY, corresponds to positions 293 to 301 of the MAGE-6 protein sequence and is presented by HLA-Cw1601 molecules. PMID: 14664500 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109434 Wed, 10 Dec 2003 07:00:00 +0100 109434 http://www.medworm.com/index.php?rid=109435&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14629132%26dopt%3DAbstract In this study, we identified a c-erbB-2/HER2/neu (HER2)-derived Th epitope (HER2 (16-30) ) and examined the role of Th epitopes in HER2-specific CD8+ T cell induction and in vivo tumor eradication, with a particular emphasis on the role of tumor cell-derived Th epitopes. Immunization of BALB/c mice using a mixture of Th epitope HER2 (16-30) and CTL epitope HER2 (63-71) administered subcutaneously with murine GM-CSF (mGM-CSF) induced a much higher level of HER2 (63-71) -specific CD8+ T cells compared with that obtained with the CTL epitope alone. HER2-unrelated OVA-derived Th epitope (OVA (323-339) ) exhibited a similar enhancing effect on HER2 (63-71) -specific CD8+ T cell induction. However, only mice immunized with HER2 (16-30) and HER2 (63-71), but not with a tumor-unrelated OVA (323-33... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109435 Fri, 21 Nov 2003 07:00:00 +0100 109435 http://www.medworm.com/index.php?rid=109436&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14580186%26dopt%3DAbstract In this study, we have analyzed the CD8+ T cell response of an ocular melanoma patient to a vaccine composed of four different tumor antigen-derived peptides administered simultaneously in incomplete Freund's adjuvant (IFA). Peptide NY-ESO-1(157-165) was remarkably immunogenic and induced a CD8+ T cell response detectable ex vivo at an early time point of the vaccination protocol. A CD8+ T cell response to the peptide analog Melan-A(26-35 A27L) was also detectable ex vivo at a later time point, whereas CD8+ T cells specific for peptide tyrosinase(368-376) were detected only after in vitro peptide stimulation. No detectable CD8+ T cell response to peptide gp100(457-466) was observed. Vaccine-induced CD8+ T cell responses declined rapidly after the initial response but increased again after ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109436 Tue, 28 Oct 2003 07:00:00 +0100 109436 http://www.medworm.com/index.php?rid=109437&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14561079%26dopt%3DAbstract Authors: Cui Z PMID: 14561079 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109437 Thu, 16 Oct 2003 06:00:00 +0100 109437 http://www.medworm.com/index.php?rid=109438&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D14533943%26dopt%3DAbstract Authors: Ayyoub M, Brehm M, Metthez G, Talbot S, Dutoit V, Taub RN, Keohan ML, Gure AO, Chen YT, Williamson B, Jungbluth AA, Old LJ, Hesdorffer CS, Valmori D The efficacy of current standard therapies for the treatment of sarcoma remains limited. With the aim of identifying target antigens relevant to the development of vaccine-based immunotherapy of sarcoma, we have addressed the relevance of tumor-specific antigens encoded by genes belonging to the SSX family as vaccine targets in sarcoma tumors. Expression of SSX-1 to -5 was analyzed in a collection of sarcoma tumors of diverse histological subtypes and in sarcoma cell lines. We found expression of at least one SSX-encoded antigen in 42% of sarcoma tumors, including 5 of 7 different histological subtypes, and in 50% of sarcoma cell ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109438 Thu, 09 Oct 2003 06:00:00 +0100 109438 http://www.medworm.com/index.php?rid=109439&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12962476%26dopt%3DAbstract Authors: Speiser DE, Rimoldi D, Batard P, Liénard D, Lejeune F, Cerottini JC, Romero P Tumor vaccines may induce activation and expansion of specific CD8 T cells which can subsequently destroy tumor cells in cancer patients. This phenomenon can be observed in approximately 5-20% of vaccinated melanoma patients. We searched for factors associated with T cell responsiveness to peptide vaccines. Peptide antigen-specific T cells were quantified and characterized ex vivo before and after vaccination. T cell responses occurred primarily in patients with T cells that were already pre-activated before vaccination. Thus, peptide vaccines can efficiently boost CD8 T cells that are pre-activated by endogenous tumor antigen. Our results identify a new state of T cell responsiveness and help to ex... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109439 Tue, 09 Sep 2003 06:00:00 +0100 109439 http://www.medworm.com/index.php?rid=109440&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12916958%26dopt%3DAbstract Authors: Donda A, Cesson V, Mach JP, Corradin G, Primus FJ, Robert B The concept of antibody-mediated targeting of antigenic MHC/peptide complexes on tumor cells in order to sensitize them to T-lymphocyte cytotoxicity represents an attractive new immunotherapy strategy. In vitro experiments have shown that an antibody chemically conjugated or fused to monomeric MHC/peptide can be oligomerized on the surface of tumor cells, rendering them susceptible to efficient lysis by MHC-peptide restricted specific T-cell clones. However, this strategy has not yet been tested entirely in vivo in immunocompetent animals. To this aim, we took advantage of OT-1 mice which have a transgenic T-cell receptor specific for the ovalbumin (ova) immunodominant peptide (257-264) expressed in the context of the... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109440 Thu, 14 Aug 2003 06:00:00 +0100 109440 http://www.medworm.com/index.php?rid=109441&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12889868%26dopt%3DAbstract Authors: Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, where... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109441 Thu, 31 Jul 2003 06:00:00 +0100 109441 http://www.medworm.com/index.php?rid=109442&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12875607%26dopt%3DAbstract We examined the expression of a panel of CT antigenic proteins in 29 patients with malignant gammopathies by immunohistochemistry using the following monoclonal antibodies (mAbs): mAb MA454 to MAGE-A1, mAb M3H67 to MAGE-A3, mAb 57B to MAGE-A4, mAb CT7-33 to CT7/MAGE-C1 and mAb ES121 to NY-ESO-1. We could detect at least one CT antigen in tumors from 27 of 29 patients. The expression pattern of MAGE-A1, -A3, -A4 and NY-ESO-1 is heterogeneous in most cases, revealing staining in <25% of the tumor cells. Monoclonal antibodies CT7-33 and M3H67 show the highest incidence of immunoreactivity. Importantly, CT-7 can also be detected on the surface of some myeloma cells by flow cytometry, and in one plasmacytoma case by immunohistochemistry. Expression of CT antigens is greater in patients with ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109442 Wed, 23 Jul 2003 06:00:00 +0100 109442 http://www.medworm.com/index.php?rid=109444&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12862418%26dopt%3DAbstract Authors: Cebon J, Jäger E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, Gibbs S, Chen Q, Karbach J, Jackson H, MacGregor DP, Sturrock S, Vaughan H, Maraskovsky E, Neumann A, Hoffman E, Sherman ML, Knuth A Preclinical studies have shown that low dose IL-12 can potentiate cytotoxic lymphocyte responses. Since previous trials have demonstrated significant toxicity from high dose recombinant human IL-12 (rhIL-12), we sought to determine an optimal biological dose for rhIL-12 at lower doses when combined with peptide antigens. Two studies were undertaken. The rhIL-12 was administered at doses of 0 (placebo), 10, 30 and 100 ng/kg, subcutaneously in one study and intravenously in the other. Apart from IL-12 dosing, the studies were identical. Subjects had evaluable stage III or IV melanoma w... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109444 Wed, 16 Jul 2003 06:00:00 +0100 109444 http://www.medworm.com/index.php?rid=109443&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12862419%26dopt%3DAbstract Authors: Li L, Schmitt A, Reinhardt P, Greiner J, Ringhoffer M, Vaida B, Bommer M, Vollmer M, Wiesneth M, Döhner H, Schmitt M Acute myeloid leukemia (AML) is a clonal disease of hematopoiesis with poor clinical outcome despite recent improvements in chemotherapy and stem cell transplantation regimens. Immunotherapy with dendritic cells (DCs) eliciting specific T cell responses to leukemia-associated antigens (LAAs) might be a therapeutic option. DCs must express HLA class I/II molecules and the costimulatory molecules CD40, CD80 and CD86 to effectively activate T cells for the subsequent lysis of leukemic blasts. The expression of these antigens on DCs generated from 15 AML patients (AML-DCs) and on DCs generated from 15 healthy volunteers (HV-DCs) was analyzed by FACS. All DCs displa... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109443 Wed, 16 Jul 2003 06:00:00 +0100 109443 http://www.medworm.com/index.php?rid=109445&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12844288%26dopt%3DAbstract Authors: Höglund P, Kärre K, Klein G As a bystander effect, immune responses against infectious organisms can damage normal cells. Immune privilege can protect such endangered tissues from immune destruction. One example is the eye where potentially devastating inflammatory reactions are prevented by active, counter-regulating processes that prevent lymphocyte activation. Recent epidemiological data from transplant patients in Sweden showed, surprisingly, that the frequency of cervical cancers did not increase in organ transplant recipients, in contrast to cancers of the vagina, vulva and anus. The same subtypes of HPV are known to be involved in the genesis of all these tumors. The immune surveillance mechanisms known to antagonize the outgrowth of virally-associated neoplasms would... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109445 Mon, 07 Jul 2003 06:00:00 +0100 109445 http://www.medworm.com/index.php?rid=109446&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12828452%26dopt%3DAbstract Authors: Mischo A, Wadle A, Wätzig K, Jäger D, Stockert E, Santiago D, Ritter G, Regitz E, Jäger E, Knuth A, Old L, Pfreundschuh M, Renner C The serological analysis of antigens by recombinant expression cloning (SEREX) has identified a multitude of new tumor antigens in many different tumor entities. These antigens can be grouped into different classes according to their specificities, with cancer/testis antigens appearing to be the most attractive candidates for vaccine development. The observation that CD8 and CD4 T-cell responses against cancer/testis antigens such as NY-ESO-1 correlate with the presence of specific antibodies demonstrates the importance of serological monitoring patients participating in vaccine trials. However, all serological assays available (Western blot, p... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109446 Fri, 27 Jun 2003 06:00:00 +0100 109446 http://www.medworm.com/index.php?rid=109447&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12812464%26dopt%3DAbstract Authors: Srivastava PK PMID: 12812464 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109447 Wed, 18 Jun 2003 06:00:00 +0100 109447 http://www.medworm.com/index.php?rid=109475&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747745%26dopt%3DAbstract Authors: Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G The identification of antigens mediating tumor rejection is an important goal of cancer immunology. The SEREX technology utilizes antibodies from cancer patients to identify candidate antigens from tumor-derived cDNA expression libraries. Using sera from a long-term surviving metastatic melanoma patient vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), we identified an antigen reported to be a putative opioid growth factor receptor (OGFr). The human immune response to OGFr exhibits three features shared with other tumor antigens. First, the protein is an intracellular antigen found in both nucleus and cytoplasm. Second, part of the antibody re... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109475 Mon, 17 Mar 2003 07:00:00 +0100 109475 http://www.medworm.com/index.php?rid=109476&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747744%26dopt%3DAbstract Authors: Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P Recognition of tumor cells by cytolytic T lymphocytes depends on cell surface MHC class I expression. As a mechanism to evade T cell recognition, many malignant cancer cells, including those of prostate cancer, down-regulate MHC class I. For the majority of human cancers, the molecular mechanism of MHC class I down regulation is unclear, although it is well established that MHC class I down-regulation is often associated with the down-regulation of multiple genes devoted to antigen presentation. Since the promyelocytic leukemia (PML) proto-oncogene controls multiple antigen-presentation genes in some murine cancer cells, we analyzed the expression of proto-oncogene PML and MHC class I i... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109476 Fri, 14 Feb 2003 07:00:00 +0100 109476 http://www.medworm.com/index.php?rid=109478&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747742%26dopt%3DAbstract Authors: Old LJ PMID: 12747742 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109478 Thu, 06 Feb 2003 07:00:00 +0100 109478 http://www.medworm.com/index.php?rid=109428&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D15017986%26dopt%3DAbstract Authors: PMID: 15017986 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109428 Thu, 06 Feb 2003 07:00:00 +0100 109428 http://www.medworm.com/index.php?rid=109477&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747743%26dopt%3DAbstract In this report, we have found that protective immunity elicited by 96tm+ tumor cells was tumor-specific and long-lasting. Both CD4+ and CD8+ T cell memory were elicited. By immunizing with tumor cells loaded with the chicken ovalbumin (ova) model antigen, we demonstrated that the priming of adoptively transferred ova-specific CD8+ T cells could occur across MHC haplotypes. The efficiency of this cross priming can be significantly increased when mice were immunized with whole cells that express both ova and cell surface gp96 (ova+96tm+). Mere mixture of soluble ova with 96tm-expressing tumor cells (ova-96tm+) was insufficient, arguing for further processing of ova and perhaps the participation of 96tm-ova complexes in this process. We further compared the relative efficiency of two whole ce... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109477 Tue, 28 Jan 2003 07:00:00 +0100 109477 http://www.medworm.com/index.php?rid=109459&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747761%26dopt%3DAbstract Authors: Binder RJ, Kumar SK, Srivastava PK Immunization of mice with in vitro reconstituted alpha2-macroglobulin-peptide complexes primes peptide-specific CTL responses. We show here using the H-Y antigenic system that naturally produced, immunogenic alpha2-macroglobulin-peptide complexes can be isolated from the sera of normal male mice. As an application of these ideas to cancer immunity, we show that the immunity evoked by alpha2-macroglobulin-peptide complexes reconstituted in vitro is effective in prophylaxis against tumors. Furthermore, complex peptide mixtures isolated from tumor lysates can be reconstituted non-covalently with alpha2-macroglobulin and such complexes elicit potent protective tumor immunity. This approach circumvents the need for prior knowledge of the identity ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109459 Wed, 18 Dec 2002 07:00:00 +0100 109459 http://www.medworm.com/index.php?rid=109460&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747760%26dopt%3DAbstract Authors: Gottfried E, Krieg R, Eichelberg C, Andreesen R, Mackensen A, Krause SW Dendritic cells (DCs) are professional antigen-presenting cells currently being discussed as a potent tool for antitumor vaccination strategies. The approach consisting of the in vitro generation of DC-tumor cell hybrids may be advantageous for individualized vaccines since there is no need for the determination of MHC-restricted tumor-associated antigens recognized by T cells. As recent vaccination studies gave varying results, we tested the impact of the fusion treatment on the cells used. Polyethylene glycol-induced fusion, as well as electrofusion, proved to be suitable for generating hybrid cells although at a low frequency. Of note, both methods also gave rise to DCs having phagocytosed apoptotic tum... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109460 Thu, 07 Nov 2002 07:00:00 +0100 109460 http://www.medworm.com/index.php?rid=109461&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747759%26dopt%3DAbstract Authors: Speiser DE, Cerottini JC, Romero P This commentary reviews the data on HLA-A2-restricted CD8 T cells specific for peptide (540-548) derived from hTERT (human telomerase reverse transcriptase). Several studies have reported the successful generation of such T cells (1, 2, 3). However, tumor recognition was observed in some, but not all, studies. More data are required to elucidate whether hTERT peptide (540-548) -specific T cells can indeed recognize and destroy tumor cells. It would be highly useful if telomerase would emerge as a universal tumor antigen that can be targeted in the cancer immunotherapy of HLA-A2 positive patients. PMID: 12747759 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109461 Mon, 14 Oct 2002 06:00:00 +0100 109461 http://www.medworm.com/index.php?rid=109462&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747758%26dopt%3DAbstract Authors: Liu Z, Lee FT, Hanai N, Smyth FE, Burgess AW, Old LJ, Scott AM The chimeric KM871 monoclonal antibody targets the GD3 disialoganglioside antigen and is under investigation for its immunotherapeutic potential in melanoma. Preclinical and phase I studies have demonstrated the biodistribution and specific tumour targeting of KM871 to metastatic melanoma in vivo, with a long half-life and lack of immunogenicity making it an attractive candidate for further clinical trials. In vitro studies have demonstrated KM871 induces high levels of cytotoxicity in both antibody-dependent cellular-cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assays. In order to investigate the potential for cytokine upregulation of KM871-mediated ADCC, freshly isolated healthy donor PBMC effe... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109462 Mon, 07 Oct 2002 06:00:00 +0100 109462 http://www.medworm.com/index.php?rid=109464&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747756%26dopt%3DAbstract Authors: Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B, Pfreundschuh M Cancer-testis (CT) genes are expressed in a variety of human cancers, but not in normal tissues except for testis, and represent promising targets for immunotherapy and gene therapy. We investigated the expression of 10 CT genes (MAGE-1, MAGE-3, MAGE-4, GAGE, NY-ESO-1, SSX-1, HOM-MEL-40/SSX-2, SSX-4, HOM-TES-14/SCP-1, and HOM-TES-85) in 21 hepatocellular carcinoma (HCC) biopsy specimens. The most frequently expressed CT genes were SSX-1 and GAGE, which were found in 8/21 (38%) HCC samples, followed by HOM-TES-14/SCP-1 (6/21 or 29%), MAGE-3 (5/21 or 24%), HOM-TES-85 and MAGE-1 (4/21 or 19% each), whereas SSX-4 and HOM-MEL-40/SSX-2 were only expressed in 2/21 cases each, MAGE-4 in one case, and NY-ESO-1 not ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109464 Thu, 19 Sep 2002 06:00:00 +0100 109464 http://www.medworm.com/index.php?rid=109463&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747757%26dopt%3DAbstract Authors: Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A NY-ESO-1 is one of the most immunogenic cancer antigens known to date, inducing humoral and cellular immune responses in a high proportion of patients with advanced NY-ESO-1-expressing cancers. The assessment of spontaneous and vaccine-induced CD8+ T cell responses has been limited to a small number of known NY-ESO-1 epitopes presented by MHC class I alleles. Recently, a new method to monitor NY-ESO-1-specific CD8+ T cell responses was introduced that does not depend on the individual MHC class I status and on predefined peptide epitopes. Antigen-presenting cells transduced with recombinant adenoviral vectors encoding NY-ESO-1 were used to stimulate CD8+ sele... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109463 Thu, 19 Sep 2002 06:00:00 +0100 109463 http://www.medworm.com/index.php?rid=109465&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747755%26dopt%3DAbstract Authors: Jäger D, Stockert E, Karbach J, Herrlinger K, Atmaca A, Arand M, Chen YT, Gnjatic S, Old LJ, Knuth A, Jäger E NY-ESO-1 is one of the most immunogenic tumor antigens known to date. Spontaneous humoral and cellular immune responses against NY-ESO-1 are detected in a substantial proportion of patients with NY-ESO-1 positive cancers. NY-ESO-1 serum antibody is dependent on the presence of NY-ESO-1+ cancer cells, and antibody titers correlate with the clinical development of the disease. NY-ESO-1 serum antibody is associated with detectable NY-ESO-1-specific CD8+ T cell reactivity. High titers of NY-ESO-1 serum antibodies are found in patients with advanced NY-ESO-1+ malignancies. Urine samples of seropositive patients with normal kidney function were tested for NY-ESO-1 antibody... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109465 Tue, 06 Aug 2002 06:00:00 +0100 109465 http://www.medworm.com/index.php?rid=109467&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747753%26dopt%3DAbstract Authors: Srinivasan R, Houghton AN, Wolchok JD DNA vaccination against tissue-restricted antigens is a strategy for cancer therapy. Immune tolerance and ignorance of self antigens has been a hurdle for this approach. We have shown that immunization with xenogeneic DNA orthologues elicits tumor immunity. One model that we have developed entails immunization of mice against tyrosinase-related protein-2 (Tyrp2) using cDNA encoding homologous human Tyrp2. A subset of mice immunized with human Tyrp2 developed antibody responses to Tyrp1. Unexpectedly, this was not simply due to cross-reactivity, as mice with anti-Tyrp1 antibodies were not usually the same animals with anti-Tyrp2 antibodies. Although autoimmune vitiligo was frequently observed in mice that had been immunized with Tyrp2, its ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109467 Fri, 19 Jul 2002 06:00:00 +0100 109467 http://www.medworm.com/index.php?rid=109466&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747754%26dopt%3DAbstract Authors: Vigneron N, Ooms A, Morel S, Degiovanni G, Van Den Eynde BJ Melanoma line LG2-MEL expresses several antigens recognized by autologous CTLs. One of them consists of a peptide derived from tyrosinase and presented by HLA-B*3503. We have identified another antigen of LG2-MEL as a peptide presented by HLA-B*4403 and resulting from a point mutation in gene OS-9. This gene is expressed in various normal tissues. It is located on chromosome 12 in the vicinity of the CDK4 locus and is frequently co-amplified with CDK4 in human sarcomas. The mutation, a C-to-T transition, changes a proline residue into a leucine at position 446 of the OS-9 protein. Mutated transcripts were found in all the melanoma sublines of LG2-MEL. None of the 184 tumor samples collected from other cancer patients ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109466 Fri, 19 Jul 2002 06:00:00 +0100 109466 http://www.medworm.com/index.php?rid=109468&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747752%26dopt%3DAbstract Authors: Dutoit V, Guillaume P, Romero P, Cerottini JC, Valmori D Recent studies in mouse models have suggested that genetic transfer of tumor antigen-specific high affinity T cell receptors (TCR) into host lymphocytes could be a viable strategy for the rapid induction of tumor-specific immunity. A previously proposed approach for the isolation of such TCRs consists in circumventing tolerance to self-restricting HLA/peptide complexes by deriving them from PMBCs of allogenic donors. Towards this aim, we used fluorescent HLA-A2 class-I/peptide soluble multimers to isolate A2-restricted CD8+ T cells specific for a previously described Melan-A peptide enhanced analog (Melan-A 26-35 A27L) from an HLA-A*0201 (A2) negative donor. We isolated two distinct groups of Melan-A 26-35 A27L-specific ... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109468 Fri, 12 Jul 2002 06:00:00 +0100 109468 http://www.medworm.com/index.php?rid=109470&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747750%26dopt%3DAbstract This study provides further evidence that SEREX is a powerful tool to identify new tumor antigens potentially relevant for immunotherapy approaches. PMID: 12747750 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109470 Fri, 28 Jun 2002 06:00:00 +0100 109470 http://www.medworm.com/index.php?rid=109469&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747751%26dopt%3DAbstract Authors: Parmiani G, Sensi M, Castelli C, Rivoltini L, Anichini A Most vaccination studies of cancer patients find no clear association between clinical and immunological responses to the vaccine. We discuss the possible kinetics of the T cell response in melanoma patients against unique or shared tumor antigens. We hypothesize that a response against unique antigens prevails during primary melanoma growth, causing the selection of tumor cells lacking most of these antigens unless these are necessary to maintain the neoplastic state. After a subset of tumor cells metastasize to the lymph nodes, T cells are activated against previously ignored shared, differentiation-like antigens, owing to a new environment where pro-inflammatory cytokines can be present. The development of a T cell re... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109469 Fri, 28 Jun 2002 06:00:00 +0100 109469 http://www.medworm.com/index.php?rid=109472&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747748%26dopt%3DAbstract Authors: Asai T, Storkus WJ, Mueller-Berghaus J, Knapp W, DeLeo AB, Chikamatsu K, Whiteside TL In previous studies, we were successful in generating HLA-A2-restricted CD8+ CTLs reactive with head and neck carcinomas (HNCs) in 4/10 cases using traditional mixed lymphocyte tumor cultures (MLTCs) employing a semi-allogeneic HLA-A2+ HNC cell line, PCI-13, as the stimulator of normal HLA-A2+ donor T lymphocytes. However, these T cell lines contained only 1-1.5% HLA-A2-restricted, tumor-reactive CD8+ CTLs, as assessed by both limiting dilution and IFN-gamma ELISPOT assays. In order to increase the success rate in generating such HNC-reactive CTL lines, we modified the procedure to allow for T cell crosspriming by autologous DCs pulsed with PCI-13 lysates. In all three attempts, HLA-A2-restri... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109472 Tue, 16 Apr 2002 06:00:00 +0100 109472 http://www.medworm.com/index.php?rid=109471&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747749%26dopt%3DAbstract Authors: Makki A, Weidt G, Blachere NE, Lefrançois L, Srivastava PK To study the role of subdominant epitopes in tumor rejection we have used EL4 tumor cells and their ovalbumin (OVA)-transfected counterpart E.G7. Immunization of mice with irradiated EL4 cells conferred protection against challenge with EL4 and E.G7. Surprisingly, immunization with irradiated E.G7 cells did not protect against a subsequent challenge with EL4 or E.G7. Growth of E.G7 tumors in E.G7 immunized mice was not due to loss of expression of OVA or MHC I by the tumor cells in vivo. Adoptive transfer of OVA-specific transgenic T cells, immunization of mice with native or heat-denatured OVA or infection with a recombinant virus expressing OVA also failed to induce rejection of E.G7 tumors. Lack of immunogenicity o... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109471 Tue, 16 Apr 2002 06:00:00 +0100 109471 http://www.medworm.com/index.php?rid=109473&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747747%26dopt%3DAbstract Authors: Mazouz N, Ooms A, Moulin V, Van Meirvenne S, Uyttenhove C, Degiovanni G Recent studies have shown the importance of triggering CD40 molecules to enhance the efficiency of dendritic cells (DCs) as antigen-presenting cells (APCs). The P198 and P1A tumor antigens, which are expressed by mastocytoma P815, have been assessed for their immunogenicity using different modes of immunization. We measured CTL responses induced in vivo with antigenic peptides P198 and P1A loaded onto bone marrow-derived DCs that had matured as a consequence of CD40-CD40L interactions. CD40L-transfected 3T3 fibroblasts were used as a source of CD40L signal. Our results show that this mode of DC activation considerably improves their ability to induce CTLs against P198 and P1A antigens in vivo as compared t... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109473 Wed, 27 Mar 2002 07:00:00 +0100 109473 http://www.medworm.com/index.php?rid=109474&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747746%26dopt%3DAbstract Authors: Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A Treatment with monoclonal antibodies (mAbs) specific for CD25 (anti-CD25 mAb) has been shown to suppress growth of a variety of different tumours in mice. These studies did not however determine whether or not anti-CD25 mAbs facilitate tumour rejection by depletion of regulatory T cells or by binding to tumour-specific effector cells. Using a murine model of melanoma we have found that treatment of mice with anti-CD25 mAb facilitates long-term CD4+ T cell-mediated tumour immunity through depletion of CD25+ regulatory cells. We further show that the effector CD4+ T cells confer long-term tumour immunity even in the presence of CD25+ regulatory cells and do not require CD8+ T cells for tumour rejection... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109474 Fri, 22 Feb 2002 07:00:00 +0100 109474 http://www.medworm.com/index.php?rid=109448&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747772%26dopt%3DAbstract Authors: Xie X, Schmits R, Renner C, Preuss D, Kubuschok B, Pfreundschuh M The identification of the antigenic stimuli of B-cell neoplasms might be of considerable importance since a causal relationship between these neoplasms and antigenic stimulation has been suggested. To date the identification of such antigens has been erratic and accidental. For a systematic search and molecular characterization of human proteins that are antigenic target structures of myeloma-associated immunoglobulins, we applied SEREX (serological analysis of antigens by recombinant cDNA expression cloning) using a testis cDNA expression library and myeloma proteins from 42 patients. A monoclonal IgA from a female patient was shown to target sperm-specific cylicin II. The specificity of the reaction was confir... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109448 Fri, 14 Dec 2001 07:00:00 +0100 109448 http://www.medworm.com/index.php?rid=109449&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747771%26dopt%3DAbstract Authors: Kufer P, Zettl F, Borschert K, Lutterbüse R, Kischel R, Riethmüller G Direct priming of naive human CD8+ and CD4+ T cells by tumor cells devoid of any intrinsic antigen presentation properties, but passively armed with recombinant proteins mediating primary and costimulatory T cell signals, was investigated. Bifunctional antibody constructs were used to specifically target costimulatory molecules such as B7-1, B7-2 and LFA-3 to the epithelial cell adhesion molecule (EpCAM), a surface antigen successfully used as target for antibody therapy of minimal residual colorectal cancer. T cell priming was monitored by flow cytometric analysis of CD45 isoform expression and confirmed by measuring typical effector functions of primed T cells known to be absent from naive T lymphocytes.... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109449 Mon, 12 Nov 2001 07:00:00 +0100 109449 http://www.medworm.com/index.php?rid=109450&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747770%26dopt%3DAbstract Authors: Wolchok JD, Srinivasan R, Perales MA, Houghton AN, Bowne WB, Blachere NE Tyrosinase-related proteins-1 and -2 (gp75/TRP-1 and TRP-2) are melanosomal membrane glycoproteins recognized by antibodies and T-cells from patients with melanoma. Xenogeneic DNA immunization against gp75/TRP-1 generates antibody-dependent tumor immunity and autoimmune depigmentation. In contrast xenogeneic TRP-2 DNA immunization induces immunity mediated by CD8+ T-cells. The role of IFN-gamma in the generation of tumor immunity and autoimmune depigmentation in these two models was investigated. No tumor protection and minimal depigmentation was observed after immunization with human TRP-2 DNA in mice deficient in IFN-gamma ligand. Repletion with recombinant murine IFN-gamma restored tumor immunity. Expe... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109450 Thu, 16 Aug 2001 06:00:00 +0100 109450 http://www.medworm.com/index.php?rid=109451&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747769%26dopt%3DAbstract Authors: Uenaka A, Hata H, Win S, Ono T, Wada H, Nakayama E The methodology of cloning genes coding for antigens recognized by T-cells from cDNA expression libraries was improved technically by using enzyme-linked immunospot (ELISPOT) assays instead of enzyme-linked immunosorbent assays (ELISA) or bioassays to detect cytokines produced by T-cells in response to antigens. Combining large and small scale ELISPOT assays for expression cloning has the following advantages compared to conventional cDNA expression cloning: i) the number of recombinant plasmids which can be screened is greater than 10,000 per well in a 24-well plate in a large scale ELISPOT assay compared to fewer than 100 per well in a 96-well plate in an IFN-gamma ELISA or a TNF-alpha bioassay; ii) the total number of recom... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109451 Fri, 13 Jul 2001 06:00:00 +0100 109451 http://www.medworm.com/index.php?rid=109452&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747768%26dopt%3DAbstract Authors: Kovalchin JT, Murthy AS, Horattas MC, Guyton DP, Chandawarkar RY Immunotherapy with gp96 was highly effective in mice bearing methylcholanthrene-induced fibrosarcomas (Meth A tumors) when treatment began 7 days or less after tumor challenge, but significantly less effective if the treatment began 9 days after challenge. Immunotherapy of pre-existing tumors showed all the hallmarks of specificity of gp96 and dose-restriction observed previously with prophylactic studies. When mice with large primary Meth A tumors were treated with surgery alone, or with surgery followed by therapy with Meth A-derived gp96, the mice that received surgery and immunotherapy did significantly better than those receiving surgery alone. The relationship between the time of initiation of immunotherapy... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109452 Fri, 27 Apr 2001 06:00:00 +0100 109452 http://www.medworm.com/index.php?rid=109453&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747767%26dopt%3DAbstract Authors: Klein G PMID: 12747767 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109453 Mon, 09 Apr 2001 06:00:00 +0100 109453 http://www.medworm.com/index.php?rid=109458&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747762%26dopt%3DAbstract Authors: Old LJ PMID: 12747762 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109458 Fri, 30 Mar 2001 07:00:00 +0100 109458 http://www.medworm.com/index.php?rid=109457&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747763%26dopt%3DAbstract Authors: Robert B, Guillaume P, Luescher I, Doucey MA, Cerottini JC, Romero P, Mach JP To combine the advantage of both the tumor targeting capacity of high affinity monoclonal antibodies (mAbs) and the potent killing properties of cytotoxic T lymphocytes (CTL), we investigated the activity of conjugates made by coupling single Fab' fragments, from mAbs specific for tumor cell surface antigens, to monomeric HLA-A2 complexes containing the immunodominant influenza-matrix peptide 58-66. In solution, the monovalent 95 kDa Fab-HLA-A2/Flu conjugates did not activate influenza-specific CTL. However, when targeted to tumor cells expressing the relevant tumor-associated antigen, the conjugates induced CTL activation and efficient tumor cell lysis, as a result of MHC/peptide surface oligomeriza... Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109457 Fri, 30 Mar 2001 07:00:00 +0100 109457 http://www.medworm.com/index.php?rid=109456&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747764%26dopt%3DAbstract Authors: Jongeneel V PMID: 12747764 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109456 Fri, 30 Mar 2001 07:00:00 +0100 109456 http://www.medworm.com/index.php?rid=109455&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747765%26dopt%3DAbstract This study adds to the growing list of breast cancer antigens defined by SEREX and to the ultimate objective of identifying the complete repertoire of immunogenic gene products in human cancer (the cancer immunome). PMID: 12747765 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109455 Fri, 30 Mar 2001 07:00:00 +0100 109455 http://www.medworm.com/index.php?rid=109454&cid=s_31092_6_f&fid=31092&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D12747766%26dopt%3DAbstract This study reports on the ability of the methylcholanthrene-induced fibrosarcoma, Meth A, as well as other tumors of varied histological origins to downregulate the lytic activity of CD8+ T cells. The suppressive activity is contact-dependent and reversible. As tumor-bearing hosts are rarely immunosuppressed systemically, these findings may explain how local events within the tumor bed subvert the specific anti-tumor immune response. PMID: 12747766 [PubMed - indexed for MEDLINE] (Source: Cancer Immunity) Cancer Immunity journals http://www.medworm.com/rss/comments.php?id=109454 Fri, 30 Mar 2001 07:00:00 +0100 109454